EP1379493A2 - Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses - Google Patents

Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses

Info

Publication number
EP1379493A2
EP1379493A2 EP02723329A EP02723329A EP1379493A2 EP 1379493 A2 EP1379493 A2 EP 1379493A2 EP 02723329 A EP02723329 A EP 02723329A EP 02723329 A EP02723329 A EP 02723329A EP 1379493 A2 EP1379493 A2 EP 1379493A2
Authority
EP
European Patent Office
Prior art keywords
compound
chr
mmol
histamine
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02723329A
Other languages
German (de)
French (fr)
Inventor
Lisa Selsam Beavers
Robert Alan Gadski
Philip Arthur Hipskind
Craig William Lindsley
Karen Lynn Lobb
James Arthur Nixon
Richard Todd Pickard
John Mehnert Schaus
Takako Takakuwa
Brian Morgan Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP1379493A2 publication Critical patent/EP1379493A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the present invention relates to histamine H3 receptor antagonists, and as such are useful in the treatment of disorders responsive to the inactivation of histamine H3 receptors, such as obesity, cognitive disorders, attention deficient disorders and the like.
  • the histamine H3 receptor (H3R) is a presynaptic autoreceptor and hetero- receptor found in the peripheral and central nervous system and regulates the release of histamine and other neurotransmitters, such as serotonin and acetylcholine.
  • the histamine H3 receptor is relatively neuron specific and inhibits the release of a number of monamines, including histamine. Selective antagonism of the histamine H3 receptor raises brain histamine levels and inhibits such activities as food consumption while minimizing non-specific peripheral consequences.
  • Antagonists of the histamine H3 receptor increase synthesis and release of cerebral histamine and other monoamines. By this mechanism, they induce a prolonged wakefulness, improved cognitive function, reduction in food intake and normalization of vestibular reflexes. Accordingly, the histamine H3 receptor is an important target for new therapeutics in Alzheimer disease, mood and attention adjustments, cognitive deficiencies, obesity, dizziness, schizophrenia, epilepsy, sleeping disorders, narcolepsy and motion sickness.
  • EP 978512 published March 1 2000 discloses non-imidazole aryloxy alkylamines discloses histamine H3 receptor antagonists but does not disclose the affinity, if any, of these antagonists for recently identified histamine receptor GPRv53, described below.
  • EP 0982300 A2 (pub.
  • March 1, 2000 discloses non-imidazole alkyamines as histamine HS receptor ligand which are similar to the subject invention by having a phenoxy core structure although the subject invention is unique in the dissimilar substitutions at the ortho, meta or para positions of the central benzene ring, the exact substitutions of the non-oxygen benzene ring substituent, and in some cases the presence of a saturated, fused heterocyclic ring appended to the central benzene core. Furthermore the compounds of this invention are highly selective for the H3 receptor (vs. other histamine receptors), and possess remarkable drug disposition properties (pharmacokinetics).
  • H1R, H2R, H3R and a newly identified receptor designated GPRv53 [(Oda T., et al., J.Biol.Chem. 275 (47): 36781-6 (2000)].
  • GPRv53 is a widely distributed receptor found at high levels in human leukocytes. Activation or inhibition of this receptor could result in undesirable side effects when targeting antagonism of the H3R receptor.
  • the identification of this new receptor has fundamentally changed histamine biology and must be considered in the development of histamine H3 receptor antagonists.
  • the present invention provides compounds that are useful as histamine H3 receptor antagonists.
  • the present invention provides compounds that are useful as selective antagonists of the histamine H3 receptor but have little or no binding affinity of GPRv53.
  • the present invention provides pharmaceutical compositions comprising antagonists of the histamine H3 receptor.
  • the present invention provides compounds, pharmaceutical compositions, and methods useful in the treatment of obesity, cognitive disorders, attention deficient disorders and other disorders associated with histamine H3 receptor.
  • the present invention is a compound structurally represented by Formula I
  • X is O, NR 7 or S
  • Rl is hydrogen
  • R2 is independently R 1 , or
  • R3 is independently C 3 -C 7 cycloalkylene, or C.- C 4 alkylene optionally substituted;
  • R4 is hydrogen, halogen, C1 -C4 alkyl,
  • R5 is hydrogen , or C1-C4 alkyl
  • R6 is hydrogen, halo or cyclized with the attached carbon atom at the R ⁇ position to form a 5 to 6 member carbon ring, cyclized with the attached carbon atom at the R ⁇ position to form a 5 to 6 member heterocyclic ring or
  • R7 is hydrogen
  • R8 is hydrogen, a bond, Ci -Cg alkyl
  • R 9 is hydrogen, halogen, Cj-Cg alkyl optionally substituted with 1 to 4 halogens,
  • the core phenoxy ring is an o, m, or p- disubstituted benzene, more preferably a p-di substituted benzene.
  • R 6 forms a bicyclic carbon ring at the R 5 position.
  • R 6 may form a bicyclic heterocyclic ring at the R 7 position.
  • X is nitrogen
  • R 4 and R 5 are independently H or CH 3
  • Rl and R2 are independently a C]-C 8 alkyl
  • R9 is a di-Ci to C 2 alkyl-amino.
  • the present invention is a pharmaceutical composition which comprises a compound of Formula I and a pharmaceutically acceptable carrier.
  • Pharmaceutical formulations of Formula I can provide a method of selectively increasing histamine levels in cells by contacting the cells with an antagonist of the histamine H3 receptor, the antagonists being a compound of Formula I.
  • the present invention further provides an antagonist of Formula I which is characterized by having little or no binding affinity for the histamine receptor GPRv53.
  • a pharmaceutical preparation of Formula I can be useful in the treatment or prevention of obesity, cognitive disorders, attention deficient disorders and the like, which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Formula I.
  • a pharmaceutical preparation of Formula I can be useful in the treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect or the treatment or prevention of eating disorders which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Formula I.
  • GPRv53 means a recently identified novel histamine receptor as described in Oda, et al, supra. Alternative names for this receptor are PORT3 or H4R.
  • H3R means to the histamine H3 receptor that inhibits the release of a number of monoamines, including histamine.
  • H1R means to the histamine HI receptor subtype.
  • H2R means to the histamine H2 receptor subtype.
  • selective H3R antagonists is defined as the ability of a compound of the present invention to block forskolin-stimulated cAMP production in response to agonist R (-) ⁇ methylhistamine.
  • Alkylene are a saturated hydrocarbyl diyl radical of straight or branched configuration made up of from 1 to 4 carbon atoms. Included within the scope of this term are methylene, 1,2 -ethane-diyl, 1,1-ethane-diyl, 1,3-propane diyl, 1,2-propane diyl, 1,3 butane-diyl, 1,4 -butane diyl, and the like.
  • C 3 -C 7 cycloalkylene are a saturated hydrocarbyldiyl radical of cyclic configuration, optionally branched, made up of from 3 to 7 carbon atoms. Included within the scope of this term are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, and the like.
  • Alkyl are one to four or one to eight carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomeric forms thereof.
  • Aryl are six to twelve carbon atoms such as phenyl, alpha -naphthyl, beta - naphthyl, m-methylphenyl, p-trifluoromethylphenyl and the like.
  • the aryl groups can also be substituted with one to 3 hydroxy, fluoro, chloro, or bromo groups.
  • Cycloalkyl are three to seven carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • Heteroaryl are six to twelve carbon atoms aryls, as described above, containing the heteroatoms nitrogen, sulfur or oxygen. Heteroaryls are pyridine, thiophene, furan, pyrimidine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pryidazinyl, 3-pyrazinyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 3- isoquinolyl, 4-isoquinolyl, 2-quinazolinyl, 4-quinazolinyl, 2-quinoxalinyl, 1-phthalazinyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-pyrazolyl, 4- pyrazolyl, 5-pyrazolyl, 2-oxazolyl
  • Heterocycle are three to twelve carbon atom cyclic aliphatic rings, wherein one or more carbon atoms is replaced by a hetero-atom which is nitrogen, sulfur or oxygen.
  • Halogen or “halo” means fluoro, chloro, bromo and iodo.
  • Composition means a pharmaceutical composition and is intended to encompass a pharmaceutical product comprising the active ingredient(s), Formula I, and the inert ingredient(s) that make up the carrier. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • unit dosage form means physically discrete units suitable as unitary dosages for human subjects and other non-human animals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier.
  • treating and “treat”, as used herein, include their generally accepted meanings, i.e., preventing, prohibiting, restraining, alleviating, ameliorating, slowing, stopping, or reversing the progression or severity of a pathological condition, described herein.
  • the present invention provides compounds of Formula I as described in detail above.
  • Another embodiments are where the phenoxy core structure is an o, m, or p- disubstituted aryl.
  • Another embodiment is a compound wherein R 6 is cyclized with the attached carbon atom at R 7 to form, including the fused benzene ring, a substituted tetrahydroisoquinoline ring.
  • Another embodiment is a compound wherein X is nitrogen, and wherein R 7 and R 8 are cyclized to form, together with X, a pyrrolidine ring, and wherein R 9 is -CH2-N-pyrrolidinyl.
  • a preferred moiety for X is independently O or N.
  • a preferred moiety for R 9 is C]-C 8 dialkylamino.
  • a more preferred embodiment is where the dialkylamino is dimethylamine
  • references to the compounds of Formula I are meant to also include the pharmaceutical salts, its enantiomers and racemic mixtures thereof. Because certain compounds of the invention contain a basic moiety (e.g., amino), the compound of Formula I can exist as a pharmaceutical acid addition salt.
  • Such salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, mono- hydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, 2-butyne-l,4 dioate, 3-hexyne-2, 5-dioate, benzoate, chlorobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hippurate, beta-hydroxybutyrate, glycollate, maleate, tart
  • the invention includes tautomers, enantiomers and other stereoisomers of the compounds also.
  • certain aryls may exist in tautomeric forms. Such variations are contemplated to be within the scope of the invention.
  • the compounds of Formula I may be prepared by several processes well known in the art.
  • the compounds of the present invention are prepared by standard alkylation or Mitsunobu chemistries and reductive animations known to one skilled in the art, or by the methods provided herein, supplemented by methods known in the art.
  • this reaction is conducted in an organic solvent such as, for example, halogenated hydrocarbons, toluene, acetonitrile and the like, preferably in the absence of moisture, at temperatures in the range about O-lOOo C, by bringing together the ingredients in contact in the solvent medium and stirring for about 10 minutes to about 48 hours at such temperatures.
  • the compounds of Formula I when existing as a diastereomeric mixture, may be separated into diastereomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof.
  • the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent.
  • any enantiomer of a compound of the formula may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration or through enantioselective synthesis.
  • Table 1 are being provided to further illustrate the present invention. They are for illustrative purposes only; the scope of the invention is not to be considered limited in any way thereby.
  • the preparation of compounds of Formula I are depicted in the schemes and procedures below.
  • Example 2 To a 100 mL round-bottom flask was placed NaH (60% dispersion, 38.4 mg, 1.0 mmol) and anhydrous THF (10 mL, 0.1 M) under an atmosphere of nitrogen. Then, a DMF solution of p-hydroxyacetophenone ( 62 mg, 0.5 mmol) was added at 0 C. After 15 minutes, a DMF solution of 3-chloro-N,N-diethyl-N-proplyamine (150 mg, 1.0 mmol) was added, and the reaction was allowed to slowly reach room temperature over 3 hours. The reaction was then quenched with water, diluted with ether and washed with water (3 x 20 mL) and brine (2x 20 mL).
  • Example 228 7-(3-Piperidin-l-yl-propoxy-3,4-dihydro-l-H-isoquinoline-2-carboxylic acid tert-butyl ester;
  • Procedure A A 100 mL dioxane solution of 7-hydroxy-3,4-dihydro-l-H-isoquinoline-2- carboxylic acid tert-butyl ester (5.0 g, 20 mmol) is stirred under N 2 as Cs 2 CO 3 (13.3 g, 43 mmol), KI (0.1 g, 0.6 mmol), then N-(3-chloropropyl)piperidine (3.9 g, 24 mmol) are added in succession. The reaction mixture is heated at 90°C for 10 hours, cooled, filtered, and concentrated to give the crude product. Purification by chromatography (SiO 2 ; 0- 10% MeOH/CH ⁇ h/ ⁇ NH-OH gradient) gives the product as an amber oil (7.5 g, 100% yield). MS(ES+)375.3(M+H) + .
  • Example 238 7-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride; Procedure B: A 50 mL CH 2 C1 2 solution of 7-(3-Piperidin-l-yl-propoxy-3,4-dihydro-l-H- isoquinoline-2-carboxylic acid tert-butyl ester (5.1 g, 13.8 mmol) is stirred under N 2 at 0- 10°C as 4N HCl/dioxane (11.5 mL, 46 mmol) is added dropwise. After the addition is complete, reaction mixture is stirred at this temperature for 30-60 min, then allowed to warm to room temperature.
  • Procedure B A 50 mL CH 2 C1 2 solution of 7-(3-Piperidin-l-yl-propoxy-3,4-dihydro-l-H- isoquinoline-2-carboxylic acid tert-butyl ester
  • Example 245 2-Methyl-7-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline: A 10 mL THF suspension of LAH (150 mg,4 mmol) is stirred under N 2 at 0-10°C as a 10 mL THF solution of 7-(3-piperidin-l-yl-propoxy-3,4-dihydro-l-H-isoquinoline-2-carboxylic acid tert-butyl ester (200 mg, 0.53 mmol) is added dropwise.
  • reaction mixture is allowed to warm to room temperature, then reaction mixture is concentrated, dissolved in dry MeOH, concentrated, triturated in Et 2 O, filtered, and dried in vacuo to give the di-HCl salt (4.5 g, 94% yld) as a white solid.
  • 2-Isopropyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline 2-Isopropyl-7- (3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 7-(3- piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (520 mg, 1.5 mmol), MP-CNBH 3 (3.2 g, 7.5 mmol), and acetone (1.1 mL, 15 mmol) via a procedure substantially analogous to Procedure C except that the SCX column is not used in purification. The product (210 mg, 44% yld) is isolated as a clear oil. MS(ES+)317.2(M+H) + .
  • Example 275 l-[7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin-2-yl]-ethanone: A 5 mL CH 2 C1 2 solution of 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (175 mg, 0.5 mmol) and NEt 3 (0.25 mL, 1J mmol) is stirred under N 2 , a 1 mL CH 2 C1 2 solution of acetyl chloride (0.043 mL, 0.6 mmol) is added, and reaction is stirred at room temp, for 5-6 hours.
  • Procedure E A 7 mL CHCl 3 /t-BuOH/MeCN (5:1:1) mixture of 7-(3-piperidin-l-yl- propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (256 mg, 0.74 mmol), resin bound DCC (1.1 g, 0.9 mmol), hydroxybenzotriazole (HOBt, 150 mg, 1.1 mmol), and thiophene-2-carboxylic acid (118 mg, 0.9 mmol) is shaken in a capped vial at room temperature for 48 hours. The reaction mixture is filtered and the resin beads washed twice alternately with MeOH, then CH 2 C1 2 .
  • 2-Dimethylamino-l-[7-(3-piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin-2-yl]- ethanone 2-Dimethylamino-l-[7-(3-piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin- 2-yl]-ethanone is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride (175 mg, 0.5 mmol), PS-DCC (800 mg, 1.1 mmol), HOBt (80 mg, 0.77 mmol), NEt 3 (0.21 mL, 1.5 mmol)and N,N-dimethylglycine (1.1 mL, 15 mmol) via a procedure substantially analogous to Procedure E except that PS-trisamine resin beads (700 mg, 2.6 mmol
  • Example 266 7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid isopropylamide: A 10 mL CH 2 C1 2 solution of 7-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-isoquinoline dihydrochloride (254 mg, 0.73 mmol), NEt 3 (0.20 mL, 1.4 mmol), isopropyl isocyanate (192 mg, 2.2 mmol), and 4-dimethylaminopyridine (12 mg, 0.1 mmol) is stirred under N 2 , at room temperature for 18 hours.
  • Example 249 2-Benzenesulfonyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline; Procedure F: A 5 L CH 2 C1 solution of 7-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-isoquinoline dihydrochloride (185 mg, 0.53 mmol) and NEt 3 (0.22 mL,1.8 mmol) is stirred under N 2 , benzenesulfonyl chloride (0.08 mL, 0.62 mmol) is added, and reaction is stirred at room temperature for 5-6 hours.
  • Procedure F A 5 L CH 2 C1 solution of 7-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-isoquinoline dihydrochloride (185 mg, 0.53 mmol) and NEt 3 (0.22 mL,1.8 m
  • Example 268 7-(3-Piperidin-l-yl-propoxy)-2-(thiophene-2-sulfonyl)-l,2,3,4-tetrahydro-isoquinoline: 7-(3-Piperidin-l-yl-propoxy)-2-(thiophene-2-sulfonyl)-l,2,3,4-tetrahydro-isoquinoline is prepared from 7-(3-piperidin-l-yl-propoxy)-l ,2,3,4-tetrahydro-isoquinoline dihydrochloride (175 mg, 0.5 mmol), NEt 3 (0.25 mL, 1.8 mmol), and thiophene-2- sulfonyl chloride (114 mg, 0.63 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the product (160 mg, 76% yld). MS(ES+)421.1(M+H) +
  • Example 284 2-Methanesulfonyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline hydrochloride: 2-Methanesulfonyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline hydrochloride is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-i soquinoline dihydrochloride (183 mg, 0.52 mmol), NEt 3 (0.25 mL, 1.8 mmol), and methanelsulfonyl chloride (0.05 mL, 0.66 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the free base product.
  • Example 286 2-(4-Methoxy-benzenesulfonyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline hydrochloride: 2-(4-Methoxy-benzenesulfonyl-7-(3-piperidin-l-yl-propoxy)- 1,2,3,4-tetrahydro-isoquinoline hydrochloride is prepared from 7-(3-piperidin-l-yl- propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (150 mg, 0.43 mmol), NEt 3 (0.21 mL, 1.5 mmol), and 4-methoxybenzenesulfonyl chloride (115 mg, 0.57 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the free base product.
  • Example 277 l- ⁇ 4-[7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-sulfonyl]-phenyl ⁇ - ethanone: l- ⁇ 4-[7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-sulfonyl]- phenylj-ethanone is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride (175 mg, 0.5 mmol), NEt 3 (0.25 mL, 1.8 mmol), and 4- acetylbenzenelsulfonyl chloride (131 mg, 0.60 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the product (85 mg, 37% y
  • Example 278 2-(4-Cyanobenzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline: 2-(4-Cyanobenzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l, 2,3,4- tetrahydro-isoquinoline is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride (175 mg, 0.5 mmol), NEt 3 (0.25 mL, 1.8 mmol), and 4- cyanobenzenesulfonyl chloride (121 mg, 0.60 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the product (157 mg, 71% yld). MS(ES+) 440.1(M+H) +
  • 6-hydroxy-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester is prepared by the procedures similar to those described in Selnick, H.G.; Smith, G. R.; Tebben, A. J.; Synth. Commun. 1995, 25, 3255-3262.
  • Example 127 6-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester: To a round-bottom flask, equipped with stir bar and septum, is placed 6-hydroxy- 3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester (1 g, 4.01 mmol), KI (599 mg, 4.01 mmol) and NaH (162 mg, 95%dry, 6.42 mmol).
  • 6-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride To a round-bottom flask, equipped with stir bar and septum, is placed 6-(3-piperidin-l-yl- propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester (1 g, 2.6 mmol), DCM (20 L) and 4M HCl/dioxane (5 L). The reaction is allowed to stir at room temperature for 3 h.
  • Example 40 Dimethyl-[3-(l,2,3,4-tetrahydro-isoquinolin-6-yloxy)-propyl]-amine dihydrochloride; M+l 235.
  • Example 140 6-[3-(2-Methyl-piperidin-l-yl)-propoxy]-l,2,3,4-tetrahydro-isoquinoline dihydrochloride; M+l 289.
  • Example 129 2-Ethyl-6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline: To a 25 mL round- bottom flask is placed 6-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (700 mg, 2.01 mol), MP-CNBH 3 (2.5 g, 6.05 mmol, 2.42 mmol/g) and DCM/MeOH (9mL/lmL). Then, acetaldehyde is added (0.7 mL, 12 mmol) and the reaction is allowed to stir overnight.
  • 6-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride 700 mg, 2.01 mol
  • MP-CNBH 3 2.5 g, 6.05 mmol, 2.42 mmol/g
  • Example 250 2-Ethyl-6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride: 2-Ethyl-6- (3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline (5.12g, 16.9 mmol) is dissolved in MeOH (50 mL), and IM HCl in ether is added dropwise (37.2 mL, 37.2 mmol) and the mixture is stirred for 10 minutes and concentrated to give the dihydrochloride salt as a white solid (6.0 g, 93%).
  • Example 143 2-Isopropyl-6-[3-(2-methyl-piperidin-l-yl)-propoxy]-l,2,3,4-tetrahydro-isoquinoline: To a flask equipped with a stir bar is placed 6-[3-(2-Methyl-piperidin-l-yl)-propoxy]-l,2,3,4- tetrahydro-isoquinoline dihydrochloride (300 mg, 0.83 mmol), acetone (excess), NaCNBH 3 (155 mg, 2.5 mmol) in MeOH (8 mL) and the mixture stirred at room temperature for 2h. The reaction mixture is diluted with water, and extracted with CH 2 C1 2 . The organic phase is dried over Na 2 SO 4 and concentrated. M+l 331, LCMS
  • Example 138 is prepared:
  • Example 178 6-(2-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid isopropylamide: To a 4 mL vial is placed 6-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-isoquinoline dihydrochloride (25.0 mg, 0.07 mmol), resin-bound Hunigs base (81 mg, 0.29 mmol, 3.54 mmol/g), resin bound DMAP (catalytic), and dry CH 2 C1 2 and isopropyl isocyanate (16 DL, 0.18 mmol). The vial is agitated by means of a lab quake shaker overnight.
  • Example 79 [3-(2-Methanesulfonyl-l,2,3,4-tetrahydro-isoquinolin-6-yloxy)-propyl]-dimethyl-amine: To a 4 mL vial is placed Dimethyl-[3-(l,2,3,4-tetrahydro-isoquinolin-6-yloxy)-propyl]- amine (24.0 mg, 0.1 mmol), resin-bound DIEA (58 mg, 0.2 mmol, 3.54 mmol/g), MsCl (12 DL, 0.15 mmol) and dry CH 2 C1 2 (2 mL). The vial is allowed to rotate overnight.
  • PS-trisamine (136 mg, 0.41 mmol, 3.0 mmol/g) is added and the reaction again allowed to rotate for 4 hours to scavenge excess MsCl. Filtration, washing with CH 2 C1 2 and concentration affords the desired urea LCMS >99% @ 230 nm and ELSD, M+l 360.
  • Example 302 2-Benzenesulfonyl-6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline: 2- Benzenesulfonyl-6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (330 mg, 0.95 mmol), NEt 3 (0.48 mL, 3.5 mmol), and benzenesulfonyl chloride (0.15 mL, 1.17 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the product as a white solid (250 mg, 63% yld). MS(ES+) 415.3(M+H) + .
  • 5-Hydroxy-3,4-dihydro-l-H-isoquinoline-2-carboxylic acid tert-butyl ester is prepared by the procedures similar to those described in Durand S.; Lusinchi, X.; Moreau, R. C. Bull. Soc. Chim. France 1961, 207, 270; and Georgian, V.; Harrison, R. J.; Skaletzky, L. L.; / Org Chem 1962, 27, 4571.
  • Example 290 5-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester is prepared from 5-Hydroxy-3,4-dihydro-l-H-isoquinoline-2-carboxylic acid tert- butyl ester (5.69 g, 22.8 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane.
  • Example 309 [5-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin-2-yl]-thiophen-2-yl- methanone is prepared from 5-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (0.256 g, 0.74 mmol) in a manner substantially analogous to Procedure E to give the title compound as an off-white solid (0.109 g, 38%). MS (ES+) 415.2
  • 8-Methoxy-l,2,3,4-tetrahydro-isoquinoline is prepared according to Shanker, P. S.; Subba Rao, G. S. R. Indian I. of Chemistry section B 1993, 32B, 1209-1213.
  • 8-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester is prepared from 8-hydroxy-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert- butyl ester (0.84 g, 3.4 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane.
  • Example 310 2-Ethyl-8-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 8- (3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (0.375 g, 1.1 mmol) in a manner substantially analogous to Procedure C to give the title compound as a yellow oil (0.124 g, 37%). MS (ES+) 303.3.
  • Example 312 [8-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin-2-yl]-thiophen-2-yl- methanone: To a mixture of 8-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (300 mg, 0.86 mmol) and NEt 3 (0.36 mL, 2.6 mmol) in CH 2 C1 2 (10 mL) is added 2-thiophene carbonyl chloride (0.10 mL, 0.95 mmol). After stirring at room temperature overnight, the mixture is partitioned between EtOAc and water.
  • Example 206 6-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-2H-isoquinolin-l-one is prepared from 6- hydroxy-3,4-dihydro-2H-isoquinolin-l-one (CAS Registry Number 22245-98-3) (0.5 g, 2.9 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane. Following aqueous workup, the crude material is purified by flash chromatography (Biotage 40M SiO 2 , elute 90/10/1 CH 2 Cl 2 /MeOH/NH 4 OH) to give the title compound as a white solid (0.516 g, 61%). MS (ES+) 289.1
  • Example 207 7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-2H-isoquinolin-l-one is prepared from 7- hydroxy-3,4-dihydro-2H-isoquinolin-l-one (CAS Registry Number 22246-05-5) (1.43 g, 8.76 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane. Following aqueous workup, the crude material is purified by flash chromatography (Biotage 40M SiO 2 , elute 90/10/1 to give the title compound as a white solid (1.11 g, 44%). MS (ES+) 289.1
  • Example 205 7-(3-Pyrrolidin-l-yl-propoxy)-3,4-dihydro-2H-isoquinolin-l-one is prepared from 7- hydroxy-3,4-dihydro-2H-isoquinolin-l-one (0.48 g, 2.94 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane and l-(3-Chloro- propyl)-pyrrolidine is used instead of N-(3-chloropropyl)pi peri dine.
  • Example 240 ⁇ l-[4-(3-Piperidin-l-yl-propoxy)-phenyl]-cyclopropyl ⁇ -carbamic acid benzyl ester is prepared from [l-(4-Hydroxy-phenyl)-cyclopropyl]-carbamic acid benzyl ester (1.21 g, 4.28 mmol), Cs 2 CO 3 (2.78 g, 8.55 mmol), KI (71 mg, 0.43 mmol), and N-(3- chloropropyl)piperidine (0.86 g, 5.34 mmol) in dioxane (50 mL) in a manner substantially analogous to Procedure A to give the product( (1.16 g, 66%). MS (ES+) 409.3.
  • 2-Morpholin-4-yl-N- ⁇ l-[4-(3-piperidin-l-yl-propoxy)-phenyl]-cyclopropyl ⁇ -acetamide l-[4-(3-Piperidin-l-yl-propoxy)-phenyl]-cyclopropylamine (0.195 g, 0.72 mmol) and morpholin-4-yl-acetic acid (0.125 g, 0.86 mmol) are dissolved in DMF, and diisopropylethylamine added (0.15 mL), followed by EDC (0.165 g, 0.86 mmol) and HOBt (0.116 g, 0.86 mmol). The reaction mixture was stirred overnight at room temperature.
  • Example 314 7-(4-Piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride: 7-(4- Piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride is prepared from
  • 2-Ethyl-7-(4-piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride 2- Ethyl-7-(4-piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride is prepared from 7-(4-piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (252 mg, OJ mmol), and acetaldehyde (0.40 mL, 7 mmol) in a manner substantially analogous to Procedure C to give the dihydrochloride product as an off white solid(125 mg, 70% yld). MS(ES+)317.2(M+H) + free base.
  • 2-Cyclohexylmethyl-7-(4-piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride 2-Cyclohexylmethyl-7-(4-piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride is prepared from 7-(4-piperidin-l-yl-butoxy)-l, 2,3,4- tetrahydro-i soquinoline dihydrochloride (175 mg, 0.48 mmol), and cyclohexanecarboxaldehyde (0.35 mL, 2.9 mmol) in a manner substantially analogous to
  • Example 208 [3-(3-Piperidin-l -yl-propox y)-benzyl]-(3-pyrrolidin-l-yl-propyl)-amine: The reductive amination is run with 3-(3-piperidin-l-yl-propoxy)-benzaldehyde (1 g, 4 mmol) and ), 3- pyrrolridin-1-yl propylamine (1 mL, 8 mmol), and MP-CNBH 3 resin(4.5g, 10.4 mmol)via a procedure substantially analogous to [2-(3-piperidin-l-yl-propoxy)-benzyl]-(3- pyrrolidin-l-yl-propyl)-amine to give the product as a yellow oil(818 mg, 58 % yld). MS(ES+)360.3(M+H) + free base.
  • Example 202 [4-(4-Piperidin-l-yl-butoxy)-benzyl]-(2-pyrrolidin-l-yl-ethyl)-amine: An 8 mL DMF solution of [4-(4-bromo-butoxy)-benzyl]-(2-pyrrolidin-l-yl-ethyl)-amine (307 mg, 0.86 mmol) and piperidine (0.22 mL, 2.2 mmol) is stirred at 90 °C for six hours under N 2 . The reaction mixture is cooled, diluted with CH 2 C1 2 , filtered, washed with brine, dried (Na 2 SO 4 ), and concentrated.
  • Example 237 2-Fluoro-N-(2-piperidin-l-yl-ethyl)-4-(3-piperidin-l-yl-propoxy)-benzamide: To a mixture of 2-Fluoro-4-(3-piperidin-l-yl-propoxy)-benzoic acid (70 mg, 0.25 mmol) and l-(2-aminoethyl)piperidine (45 DL, 0.3 mmol) in DMF (5 mL) was added EDC (58 mg, 0.3 mmol), HOBT (40 mg, 0.3 mmol), and diisopropylethyl amine (52 Dl, 0.3 mmol). The mixture was stirred at room temperature overnight.
  • EDC 58 mg, 0.3 mmol
  • HOBT 40 mg, 0.3 mmol
  • diisopropylethyl amine 52 Dl, 0.3 mmol
  • This compound was synthesized according to the method described in the preparation of (5).
  • Example 209 This compound was synthesized according to the method described in the preparation of Example 261.
  • Example 131 Trisamine To a 4 mL vial was placed 101 (28.5 mg, 0.1 mmol), resin-bound DCC (170 mg, 0.16 mmol, 0.94 mmol/g), HOBt (16 mg, 0.12 mmol), amine (13 uL, 0.08 mmol) and a 5:1:1 mixture of CHCl 3 :CH 3 CN:tBuOH. The vial was agitated by means of a lab quake shaker overnight. In the morning, PS-trisamine (134 mg, 0.4 mmol, 3.0 mmol/g) was added and the reaction again allowed to rotate overnight to scavenge excess carboxylic acid and
  • keto-phenol 500 mg, 3 mmol
  • CsCO 3 1.99 g, 6 mmol
  • KI KI
  • Example 94 Example 94, and 192.
  • Example 192 can be made by a substantially analogous procedure, Observed mass 360. The following examples are made by a substantially analogous procedure:
  • Example 142 To a round-bottom flask, equipped with stir bar and septum, was placed (103) (300 mg, 1.03 mmol), KI (230 mg, 1.54 mmol) and NaH (78 mg, 95%dry, 3.09 mmol). Then, dry DMF (20 mL, 0.5 M) was added via syringe followed by chloroethylpiperidine (285 mg, 1.54 mmol). The reaction was allowed to stir at 50 degrees overnight. In the morning, the reaction was quenched with water, extracted into EtOAc (3 x 20 mL) and dried over brine. Column chromatography in 9:1 DCM:MeOH afforded 631934 an yellow oil (300 mg, 79%). Mass sec hit M+l, 404; LCMS >95% @ 230 nm and ELSD.
  • Example 15 The solution of diisopropylazodicarboxylate(3.93 ml, 20 mmoles) in 20 ml anhydrous THF was added dropwise with stirring to the cold solution of 4- hydroxyacetophenone(2.18 g, 16 mmoles), 3-diethylaminopropanol(2.23 ml, 15 mmoles) and triphenylphosphine(4.98 g, 19 mmoles) in 50 ml anhydrous THF over 45 minutes. The reaction was stirred in an ice bath for one hour and at room temperature for 18 hours. The solvent was evaporated and ether was added. This solution was extracted with dilute HC1(1.0 N) four times.
  • the compound of Formula I is preferably formulated in a unit dosage form prior to administration. Therefore, yet another embodiment of the present invention is a pharmaceutical composition comprising a compound of Formula I and one or more pharmaceutically acceptable carriers, diluents or excipients.
  • the active ingredient (Formula I compound) will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container.
  • a carrier When the carrier serves as a diluent, it may be a solid, semisolid or liquid material that acts as a vehicle, excipient, or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosol (as a solid or in a liquid medium), soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • Suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propylhydroxybenzoates, talc, magnesium stearate and mineral oil.
  • the formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents.
  • compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
  • the compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e., antihistaminic activity and the like.
  • Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
  • Liquid form preparations include solutions, suspensions and emulsions.
  • Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
  • a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
  • a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration
  • liquid forms include solutions, suspensions and emulsions.
  • the compounds of the invention may also be deliverable transdermally.
  • the transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as a re conventional in the art for this purpose.
  • the compound is administered orally.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
  • the quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 0.01 milligrams to about 1,000 milligrams, preferably from about 0.01 to about 950 milligrams, more preferably from about 0.01 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application.
  • the actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art.
  • the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day. Utility
  • Compounds of Formula I are effective as histamine H3 receptor antagonists. More particularly, these compounds are selective histamine H3 receptor antagonists that have little or no affinity for histamine receptor GPRv53(H4R). As selective antagonists, the compounds of Formula I are useful in the treatment of diseases, disorders, or conditions responsive to the inactivation of the histamine H3 receptor, including but not limited to obesity and other eating-related disorders. It is postulated that selective antagonists of H3R will raise brain histamine levels and possibly that of other monoamines resulting in inhibition of food consumption while minimizing peripheral consequences. Although a number of H3R antagonists are known in the art, none have proven to be satisfactory obesity drugs. There is increasing evidence that histamine plays an important role in energy homeostasis.
  • Histamine acting as a neurotransmitter in the hypothalamus, suppressed appetite. Histamine is an almost ubiquitous amine found in many cell types and it binds to a family of G protein-coupled receptors (GPCRs). This family provides a mechanism by which histamine can elicit distinct cellular responses based on receptor distribution. Both the H1R and H2R are widely distributed. H3R is primarily expressed in the brain, notably in the thalamus and caudate nucleus. High density of expression of H3R was found in feeding center of the brain. A novel histamine receptor GPRv53 has been recently identified.
  • GPCRs G protein-coupled receptors
  • GPRv53 is found in high levels in peripheral white blood cells; only low levels have been identified in the brain by some investigators while others cannot detect it in the brain. However, any drug discovery effort initiated around H3R must consider GPRv53 as well as the other subtypes.
  • inventive compounds can readily be evaluated by using a competitive inhibition Scintillation Proximity Assay (SPA) based on a H3R binding assay using [3H] methylhistamine as ligand.
  • Stable cell lines including but not limited to HEK can be transfected with cDNA coding for H3R to prepare membranes used for the binding assay. The technique is illustrated below (Example 3) for the histamine receptor subtypes.
  • Membranes isolated as described in Example 3 were used in a [35S]GTP ⁇ S functional assay. Binding of [35S]GTP ⁇ S to membranes indicates agonist activity.
  • Compounds of the invention of Formula I were tested for their ability to inhibit binding in the presence of agonists. Alternately, the same transfected cell lines were used for a cAMP assay wherein H3R agonists inhibited forskolin-activated synthesis of cAMP.
  • Compounds of Formula I were tested for their ability to permit forskolin -stimulated cAMP synthesis in the presence of agonist. Preparation of Histamine Receptor Subtype Membranes A.
  • H1R membranes cDNA for the human histamine 1 receptor was cloned into a mammalian expression vector containing the CMV promoter (pcDNA3.1(+), Invitogen) and transfected into HEK293 cells using the FuGENE Tranfection Reagent (Roche Diagnostics Corporation). Transfected cells were selected using G418 (500 ⁇ /ml). Colonies that survived selection were grown and tested for histamine binding to cells grown in 96-well dishes using a scintillation proximity assay (SPA) based radioligand binding assay.
  • SPA scintillation proximity assay
  • Astemizole (lO ⁇ M, Sigma #A6424) was added to appropriate wells to determine nonspecific binding. Plates were covered with FasCal and incubated at room temperature for 120 minutes. Following incubation, plates were centrifuged at l,000rpm ( ⁇ 800g) for 10 minutes at room temperature. Plates were counted in a Wallac Trilux 1450 Microbeta scintillation counter. Several clones were selected as positive for binding, and a single clone (H1R40) was used to prepare membranes for binding studies. Cell pellets, representing -10 grams, were resuspended in 30ml assay buffer, mixed by vortexing, and centrifuged (40,000g at 4°C) for 10 minutes.
  • H2R10 a single clone (H2R10) was used to prepare membranes for binding studies. Five micrograms of protein was used per well in the SPA receptor-binding assay.
  • H3R membranes cDNA for the human histamine 3 receptor was cloned and expressed as described in Example 1, above.
  • Transfected cells were selected using G418 (500 ⁇ /ml), grown, and tested for histamine binding by the SPA described above.
  • Thioperimide was added to determine non-specific binding.
  • Several clones were selected as positive for binding, and a single clone (H3R8) was used to prepare membranes for binding studies described above. Five micrograms of protein was used per well in the SPA receptor-binding assay.
  • Example 1 Transfected cells were selected, tested for histamine binding, and selected.
  • HEK293 GPRv53 50 cells were grown to confluency in DMEM F12 (Gibco) supplemented with 5 % FBS and 500 ug/ml G418 and washed with Delbecco's PBS (Gibco) and harvested by scraping.
  • Whole cells were homogenized with a Polytron tissuemizer in binding buffer, 50 mM Tris pH 7.5. Cell lysates, 50 ug, were incubated in 96 well dishes with 3 nM (3H) Histamine and compounds in binding buffer for 2 hours at room temperature.
  • Lysates were filtered through glass fiber filters (Perkin Elmer) with a Tomtec cell harverster. Filters were counted with melt-on scintillator sheets (Perkin Elmer) in a Wallac Trilux 1450 Microbeta Scintillation counter for 5 minutes.
  • HEK293 H3R8 cells prepared as described above were seeded at a density of 50,000 cells/well and grown overnight in DMEM/F12 (Gibco) supplemented with 5 % FBS and 500 ug/ml G418. The next day tissue culture medium was removed and replaced with 50 ⁇ l cell culture medium containing 4 mM 3-isobutyl-l-methylxanthine (Sigma) and incubated for 20 minutes at room temperature. Antagonist were added in 50 ⁇ l cell culture medium and incubated for 20 minutes at room temperature.
  • Agonist R (-) ⁇ methylhistamine (RBI) at a dose response from lxlO "10 to lxlO "5 M was then added to the wells in 50 ⁇ l cell culture medium and incubated for 5 minutes at room temperature. Then 50 ⁇ l of cell culture medium containing 20 ⁇ M Forskolin (Sigma) was added to each well and incubated for 20 minutes at room temperature. Tissue culture medium was removed and cells were lysed in 0.1M HCl and cAMP was measured by ELISA (Assay Designs, Inc.).
  • [35S] GTP ⁇ [S] Binding Assay Antagonist activity of selected compounds was tested for inhibition of [35S] GTP ⁇ [S] binding to H3R membranes in the presence of agonists. Assays were run at room temperature in 20 mM HEPES, 100 mM NaCl ,5 mM MgCl 2 and 10 uM GDP at pH 7.4 in a final volume of 200 ul in 96-well Costar plates. Membranes isolated from H3R8- expressing HEK293 cell line (20 ug/well) and GDP were added to each well in a volume of 50 ⁇ l assay buffer.
  • Antagonist was then added to the wells in a volume of 50 ⁇ l assay buffer and incubated for 15 minutes at room temperature.
  • Agonist R(-)alpha methylhistamine (RBI) at either a dose response from lxlO "10 to lxlO "5 M or fixed concentration of 100 nM were then added to the wells in a volume of 50 ⁇ l assay buffer and incubated for 5 minutes at room temperature.
  • GTP ⁇ [35S] was added to each well in a volume of 50 ⁇ l assay buffer at a final concentration of 200 pM, followed by the addition of 50 ⁇ l of 20 mg/ml WGA coated SPA beads (Amersham).
  • Non-imidazole containing histamine H3 receptor antagonists disclosed in the literature generally have very poor pharmacokinetic properties (see J. Apelt, et al, J. Med. Chem. 2002, 45, 1128-1141). Compounds of this invention have markedly and unexpectedly improved pharmacokinetic properties.
  • Examples 131 and 271 were analyzed using LC/MS/MS.
  • compound example 131 was found to have an oral bioavailability of 58% (AUC 0-24hr; po/iv ratio) and an oral half-life of 10.4 + 4.2 hours (+SEM).
  • Compound example 271 was found to have an oral bioavailability of 69% (AUC 0-24hr; po/iv ratio) and an oral half-life of 71.9 ⁇ 3.3 hours ( ⁇ SEM).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereofwhich have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor -related diseases.

Description

NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND
THERAPEUTIC USES
BACKGROUND OF THE INVENTION
The present invention relates to histamine H3 receptor antagonists, and as such are useful in the treatment of disorders responsive to the inactivation of histamine H3 receptors, such as obesity, cognitive disorders, attention deficient disorders and the like. The histamine H3 receptor (H3R) is a presynaptic autoreceptor and hetero- receptor found in the peripheral and central nervous system and regulates the release of histamine and other neurotransmitters, such as serotonin and acetylcholine. The histamine H3 receptor is relatively neuron specific and inhibits the release of a number of monamines, including histamine. Selective antagonism of the histamine H3 receptor raises brain histamine levels and inhibits such activities as food consumption while minimizing non-specific peripheral consequences. Antagonists of the histamine H3 receptor increase synthesis and release of cerebral histamine and other monoamines. By this mechanism, they induce a prolonged wakefulness, improved cognitive function, reduction in food intake and normalization of vestibular reflexes. Accordingly, the histamine H3 receptor is an important target for new therapeutics in Alzheimer disease, mood and attention adjustments, cognitive deficiencies, obesity, dizziness, schizophrenia, epilepsy, sleeping disorders, narcolepsy and motion sickness.
The majority of histamine H3 receptor antagonists to date resemble histamine in possessing an imidazole ring generally substituted in the 4(5) position (Ganellin et al., Ars Pharmaceutica, 1995, 36:3, 455-468). A variety of patents and patent applications directed to antagonists and agonists having such structures include EP 197840, EP 494010, WO 97/29092, WO 96/38141, and WO96/38142. These imidazole-containing compounds have the disadvantage of poor blood-brain barrier penetration, interaction with cytochrome P-450 proteins, and hepatic and ocular toxicities. Non-imidazole neuroactive compounds such as beta histamines (Arrang, Eur. J.
Pharm. 1985, 111:72-84) demonstrated some histamine H3 receptor activity but with poor potency. EP 978512 published March 1, 2000 discloses non-imidazole aryloxy alkylamines discloses histamine H3 receptor antagonists but does not disclose the affinity, if any, of these antagonists for recently identified histamine receptor GPRv53, described below. EP 0982300 A2 (pub. March 1, 2000) discloses non-imidazole alkyamines as histamine HS receptor ligand which are similar to the subject invention by having a phenoxy core structure although the subject invention is unique in the dissimilar substitutions at the ortho, meta or para positions of the central benzene ring, the exact substitutions of the non-oxygen benzene ring substituent, and in some cases the presence of a saturated, fused heterocyclic ring appended to the central benzene core. Furthermore the compounds of this invention are highly selective for the H3 receptor (vs. other histamine receptors), and possess remarkable drug disposition properties (pharmacokinetics).
Histamine mediates its activity via four receptor subtypes, H1R, H2R, H3R and a newly identified receptor designated GPRv53 [(Oda T., et al., J.Biol.Chem. 275 (47): 36781-6 (2000)]. Although relatively selective ligands have been developed for H1R, H2R and H3R, few specific ligands have been developed that can distinguish H3R from GPRv53. GPRv53 is a widely distributed receptor found at high levels in human leukocytes. Activation or inhibition of this receptor could result in undesirable side effects when targeting antagonism of the H3R receptor. Furthermore, the identification of this new receptor has fundamentally changed histamine biology and must be considered in the development of histamine H3 receptor antagonists.
Because of the unresolved deficiencies of the compounds described above, there is a continuing need for improved methods and compositions to treat disorders associated with histamine H3 receptors.
The present invention provides compounds that are useful as histamine H3 receptor antagonists. In another aspect, the present invention provides compounds that are useful as selective antagonists of the histamine H3 receptor but have little or no binding affinity of GPRv53. In yet another aspect, the present invention provides pharmaceutical compositions comprising antagonists of the histamine H3 receptor.
In yet another aspect, the present invention provides compounds, pharmaceutical compositions, and methods useful in the treatment of obesity, cognitive disorders, attention deficient disorders and other disorders associated with histamine H3 receptor. SUMMARY OF THE INVENTION
The present invention is a compound structurally represented by Formula I
or pharmaceutically acceptable salts thereof wherein:
X is O, NR7 or S;
Rl is hydrogen,
Cj-Cg alkyl optionally substituted with 1 to 4 halogens,
(CHR5)n-C3-C7 cycloalkyl,
(CHR5)n aryl,
(CHR5)n heteroaryl, or (CHR5)n-O(CHR5)n-aryl;
R2 is independently R1, or
COR! > or cyclized with the attached nitrogen atom at the R-** position to form a 4, 5, or 6 member carbon ring, wherein one of said carbons is optionally replaced by one of
O, S, NRl or CO, or wherein the ring formed by R1 and R2 is optionally substituted one to two times with C1-C4 alkyl;
R3 is independently C3-C7 cycloalkylene, or C.- C4 alkylene optionally substituted; R4 is hydrogen, halogen, C1 -C4 alkyl,
(CHR5)n-C3-C7 cycloalkyl,
(CHR5)n aryl,
(CHR5)n heteroaryl,
(CHR5)n-O(CHR5)n-aryl or
CO or cyclized with R-5 to from a cyclopropyl ring;
R5 is hydrogen , or C1-C4 alkyl;
R6 is hydrogen, halo or cyclized with the attached carbon atom at the R^ position to form a 5 to 6 member carbon ring, cyclized with the attached carbon atom at the R^ position to form a 5 to 6 member heterocyclic ring or
R7 is hydrogen,
C^-Cg alkyl optionally substituted with 1 to 4 halogens,
(CHR5)n-C -C7 cycloalkyl,
(CHR5)n aryl, (CHR5)n heteroaryl,
(CHR5)n-O(CHR5)n-aryl,
SO2R1 or Cyclized with attached carbon on R to from a 5, 6, or 7 membered carbon ring optionally substituted with R9- CF3, or CN, optionally one of the said carbons is replaced by N. NRi. CO;
R8 is hydrogen, a bond, Ci -Cg alkyl
-SO2 R9, -CO2 R10, -CO R9,
-CONH R10;
R9 is hydrogen, halogen, Cj-Cg alkyl optionally substituted with 1 to 4 halogens,
C3-C7 cycloalkyl, aryl,
CH2 aryl, heteroaryl, heterocycle,
-O(CHR5)n-aryl,
-COR1, -CONR1 R2, -SO2R1, -OR1,
-N(Ri)2, -NR1 R2, -CH2NR1 R2, -CONR1 R2
-NHSO2R1,
-NO2,
-CO2R1, -SO2N(Rl)2,
-S(O)nRl, -OCF3> -CH2SR5, ydrogen, halogen,
Cj-Cg alkyl optionally substituted with 1 to 4 halogens, C3-C7 cycloalkyl, aryl,
CH2 aryl, heteroaryl, heterocycle,
-COR1,
-CONR1 R2,
-SO2R1, -N(R**-)2,
-NR1 R2, -CH2NR1 R2,
-CONR1 R2 -CO2R1, -SO2N(R1)2)
-SCO^R1, -CH2SR5, and n is 0 - 4.
In preferred embodiments of Formula I the core phenoxy ring is an o, m, or p- disubstituted benzene, more preferably a p-di substituted benzene. In alternative embodiments R6 forms a bicyclic carbon ring at the R5 position. Alternatively, R6 may form a bicyclic heterocyclic ring at the R7 position. Preferably, X is nitrogen, R4 and R5 are independently H or CH3, Rl and R2 are independently a C]-C8 alkyl and R9 is a di-Ci to C2 alkyl-amino.
The present invention is a pharmaceutical composition which comprises a compound of Formula I and a pharmaceutically acceptable carrier. Pharmaceutical formulations of Formula I can provide a method of selectively increasing histamine levels in cells by contacting the cells with an antagonist of the histamine H3 receptor, the antagonists being a compound of Formula I.
The present invention further provides an antagonist of Formula I which is characterized by having little or no binding affinity for the histamine receptor GPRv53. Thus, a pharmaceutical preparation of Formula I can be useful in the treatment or prevention of obesity, cognitive disorders, attention deficient disorders and the like, which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Formula I. In addition, a pharmaceutical preparation of Formula I can be useful in the treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect or the treatment or prevention of eating disorders which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Formula I.
DETAILED DESCRIPTION OF THE INVENTION Throughout the instant application, the following terms have the indicated meanings:
The term "GPRv53" means a recently identified novel histamine receptor as described in Oda, et al, supra. Alternative names for this receptor are PORT3 or H4R. The term "H3R" means to the histamine H3 receptor that inhibits the release of a number of monoamines, including histamine.
The term "H1R" means to the histamine HI receptor subtype. The term "H2R" means to the histamine H2 receptor subtype. The term "selective H3R antagonists" is defined as the ability of a compound of the present invention to block forskolin-stimulated cAMP production in response to agonist R (-)α methylhistamine.
"Alkylene" are a saturated hydrocarbyl diyl radical of straight or branched configuration made up of from 1 to 4 carbon atoms. Included within the scope of this term are methylene, 1,2 -ethane-diyl, 1,1-ethane-diyl, 1,3-propane diyl, 1,2-propane diyl, 1,3 butane-diyl, 1,4 -butane diyl, and the like.
"C3-C7 cycloalkylene" are a saturated hydrocarbyldiyl radical of cyclic configuration, optionally branched, made up of from 3 to 7 carbon atoms. Included within the scope of this term are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, and the like.
"Alkyl" are one to four or one to eight carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomeric forms thereof.
"Aryl" are six to twelve carbon atoms such as phenyl, alpha -naphthyl, beta - naphthyl, m-methylphenyl, p-trifluoromethylphenyl and the like. The aryl groups can also be substituted with one to 3 hydroxy, fluoro, chloro, or bromo groups.
"Cycloalkyl" are three to seven carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
"Heteroaryl" are six to twelve carbon atoms aryls, as described above, containing the heteroatoms nitrogen, sulfur or oxygen. Heteroaryls are pyridine, thiophene, furan, pyrimidine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pryidazinyl, 3-pyrazinyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 3- isoquinolyl, 4-isoquinolyl, 2-quinazolinyl, 4-quinazolinyl, 2-quinoxalinyl, 1-phthalazinyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-pyrazolyl, 4- pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5- thiazolyl, 2-indolyl, 3-indolyl, 3-indazolyl, 2-benzoxazolyl, 2-benzothiazolyl, 2- benzimidazolyl, 2-benzofuranyl, 3-benzofuranyl, 2-furanyl, 3-furanyl, 2-thienyl, 3- thienyl, 2-pyrrolyl, 3-pyrrolyl, l,2,4-oxadiazol-3-yl, l,2,4-oxadiazol-5-yl, 1,2,4- thiadiazol-3-yl, l,2,4-thiadiazol-5-yl, l,2,4-triazol-3-yl, l,2,4-triazol-5-yl, 1,2,3,4- tetrazol-5-yl, 5-oxazolyl, 1-pyrrolyl, 1-pyrazolyl, 1,2,3-triazol-l-yl, 1,2,4-triazol-l-yl, 1- tetrazolyl, 1-indolyl, 1-indazolyl, 2-isoindolyl, 1-purinyl, 3-isothiazolyl, 4-isothiazolyl, 5- isothiazolyl. "Heterocycle" are three to twelve carbon atom cyclic aliphatic rings, wherein one or more carbon atoms is replaced by a hetero-atom which is nitrogen, sulfur or oxygen. "Halogen" or "halo" means fluoro, chloro, bromo and iodo. "Composition" means a pharmaceutical composition and is intended to encompass a pharmaceutical product comprising the active ingredient(s), Formula I, and the inert ingredient(s) that make up the carrier. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
The term "unit dosage form" means physically discrete units suitable as unitary dosages for human subjects and other non-human animals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier.
The terms "treating" and "treat", as used herein, include their generally accepted meanings, i.e., preventing, prohibiting, restraining, alleviating, ameliorating, slowing, stopping, or reversing the progression or severity of a pathological condition, described herein.
In one embodiment, the present invention provides compounds of Formula I as described in detail above. Another embodiments are where the phenoxy core structure is an o, m, or p- disubstituted aryl. Another embodiment is a compound wherein R6 is cyclized with the attached carbon atom at R7 to form, including the fused benzene ring, a substituted tetrahydroisoquinoline ring. Another embodiment is a compound wherein X is nitrogen, and wherein R7 and R8 are cyclized to form, together with X, a pyrrolidine ring, and wherein R9 is -CH2-N-pyrrolidinyl. A preferred moiety for X is independently O or N. A preferred moiety for R9 is C]-C8 dialkylamino. A more preferred embodiment is where the dialkylamino is dimethylamine
It will be understood that, as used herein, references to the compounds of Formula I are meant to also include the pharmaceutical salts, its enantiomers and racemic mixtures thereof. Because certain compounds of the invention contain a basic moiety (e.g., amino), the compound of Formula I can exist as a pharmaceutical acid addition salt. Such salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, mono- hydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, 2-butyne-l,4 dioate, 3-hexyne-2, 5-dioate, benzoate, chlorobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hippurate, beta-hydroxybutyrate, glycollate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like salts.
As stated earlier, the invention includes tautomers, enantiomers and other stereoisomers of the compounds also. Thus, as one skilled in the art knows, certain aryls may exist in tautomeric forms. Such variations are contemplated to be within the scope of the invention.
The compounds of Formula I may be prepared by several processes well known in the art. The compounds of the present invention are prepared by standard alkylation or Mitsunobu chemistries and reductive animations known to one skilled in the art, or by the methods provided herein, supplemented by methods known in the art. Generally, this reaction is conducted in an organic solvent such as, for example, halogenated hydrocarbons, toluene, acetonitrile and the like, preferably in the absence of moisture, at temperatures in the range about O-lOOo C, by bringing together the ingredients in contact in the solvent medium and stirring for about 10 minutes to about 48 hours at such temperatures.
The compounds of Formula I, when existing as a diastereomeric mixture, may be separated into diastereomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof. The pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent. Alternatively, any enantiomer of a compound of the formula may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration or through enantioselective synthesis. The Examples shown in Table 1 below are being provided to further illustrate the present invention. They are for illustrative purposes only; the scope of the invention is not to be considered limited in any way thereby. The preparation of compounds of Formula I, are depicted in the schemes and procedures below.
Scheme 1.
Scheme 2
Preparation of N-1 l-r4-(3-Dimethylamino-propoxy)-phenyl-N\N'-dimethyl-ethane-L2- di amine
Example 2 To a 100 mL round-bottom flask was placed NaH (60% dispersion, 38.4 mg, 1.0 mmol) and anhydrous THF (10 mL, 0.1 M) under an atmosphere of nitrogen. Then, a DMF solution of p-hydroxyacetophenone ( 62 mg, 0.5 mmol) was added at 0 C. After 15 minutes, a DMF solution of 3-chloro-N,N-diethyl-N-proplyamine (150 mg, 1.0 mmol) was added, and the reaction was allowed to slowly reach room temperature over 3 hours. The reaction was then quenched with water, diluted with ether and washed with water (3 x 20 mL) and brine (2x 20 mL). Concentration in vacuo afforded 114 mg (92%) of an off-white solid. LCMS indicated a purity of 95% and hit the mass, 249.1. This material was then dissolved in ethanol (4 mL, 0.1M) and 1-N, N-dimethylamino-2-N- methylaminoethane (114 mg, 0.45 mmol) was added. After 15 minutes at room temperature, NaCNBH3 (56 mg, 0.9 mmol) was added and the reaction was allowed to stir overnight at room temperature. The reaction was then with water, diluted with ether and washed with water (3 x 20 mL) and brine (2x 20 mL). Concentration in vacuo afforded 134 mg (93%) of an orange oil. Column chromatography (9:1, CH2Cl2:MeOH) afforded an orange oil. LCMS indicated a purity of 99% and hit the mass, 321.2.
7-OH tetrahydroisoquinoline series
7-Hydroxy-3,4-dihydro-l-H-isoquinoline-2-carboxylic acid tert-butyl ester is prepared by the procedure described in Kucznierz, et.al., J. Med. Chem. 1998, 41, 4983-4994. MS(ES- ) 248.1 (M-H)".
Example 228 7-(3-Piperidin-l-yl-propoxy-3,4-dihydro-l-H-isoquinoline-2-carboxylic acid tert-butyl ester;
Procedure A: A 100 mL dioxane solution of 7-hydroxy-3,4-dihydro-l-H-isoquinoline-2- carboxylic acid tert-butyl ester (5.0 g, 20 mmol) is stirred under N2 as Cs2CO3 (13.3 g, 43 mmol), KI (0.1 g, 0.6 mmol), then N-(3-chloropropyl)piperidine (3.9 g, 24 mmol) are added in succession. The reaction mixture is heated at 90°C for 10 hours, cooled, filtered, and concentrated to give the crude product. Purification by chromatography (SiO2; 0- 10% MeOH/CH^h/^NH-OH gradient) gives the product as an amber oil (7.5 g, 100% yield). MS(ES+)375.3(M+H)+.
Example 238 7-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride; Procedure B: A 50 mL CH2C12 solution of 7-(3-Piperidin-l-yl-propoxy-3,4-dihydro-l-H- isoquinoline-2-carboxylic acid tert-butyl ester (5.1 g, 13.8 mmol) is stirred under N2 at 0- 10°C as 4N HCl/dioxane (11.5 mL, 46 mmol) is added dropwise. After the addition is complete, reaction mixture is stirred at this temperature for 30-60 min, then allowed to warm to room temperature. A white precipitate forms and dry MeOH is added until clear solution is obtained. Additional 4N HCl/dioxane (11.0 mL, 44 mmol) is added dropwise. After the addition is complete, reaction mixture is stirred at room temperature. Reaction is followed by TLC (SiO2 plate, CHgCl/MeOH/N^OH; 25/5/1) until starting material consumed (4-5 h). Reaction mixture is concentrated, dissolved in dry MeOH, concentrated, triturated in Et2O, filtered, and dried in vacuo to give the di-HCl salt (4.5 g, 94% yield) as a white solid. MS(ES+)275.3(M+H)+free base.
Example 245 2-Methyl-7-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline: A 10 mL THF suspension of LAH (150 mg,4 mmol) is stirred under N2 at 0-10°C as a 10 mL THF solution of 7-(3-piperidin-l-yl-propoxy-3,4-dihydro-l-H-isoquinoline-2-carboxylic acid tert-butyl ester (200 mg, 0.53 mmol) is added dropwise. Reaction mixture is allowed to warm to room temperature, refluxed 90 minutes, cooled to 0-10°C, quenched with H O and 15% aqueous NaOH, filtered, and the filtrate concentrated to give crude product. Material is purified by chromatography (SiO2; 0-10% MeOH/CH-Cb/^NHtOH gradient)to give the product (82 mg, 54% yld). MS(ES+)289.1(M+H)+.
Example 271 2-Ethyl-7-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride; Procedure C: An 80 mL CH2Cl2/MeOH (9:1) solution of 7-(3-piperidin-l-yl-propoxy)- 1,2,3,4-tetrahydro-isoquinoline dihydrochloride (658972)(2.95 g, 8.5mmol) is stirred under N2, the MP-CNBH3 resin(15 g, 38 mmol) added, the acetaldehyde (5 mL, 89 mmol) added, the pH is adjusted to ~4 with glacial AcOH and reaction mixture stirred at room temperature for 18-20 hours. The reaction mixture is filtered and the resin beads washed twice alternately with MeOH, then CH2C12. The filtrate is concentrated and the residue is purified by chromatography (SCX-MeOH wash, elute 2M NH3/MeOH; then (SiO2; 0- 10% MeOH/CH2Cl2/l%NH4OH gradient) to give the pure free base. Procedure D; A 50 mL THF/MeOH (1:1) solution of the free base (1.52 g, 5 mmol) is stirred under N2 at 0-10°C as IN HCl/Et2O (11.5 mL, 11.5 mmol) is added dropwise. After the addition is complete, reaction mixture is allowed to warm to room temperature, then reaction mixture is concentrated, dissolved in dry MeOH, concentrated, triturated in Et2O, filtered, and dried in vacuo to give the di-HCl salt (4.5 g, 94% yld) as a white solid. MS(ES+)303.3(M+H)+free base.
Example 292 (di-HCL salt) Example 273 (free base)
2-Cyclohexylmethyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride: 2-Cyclohexylmethyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride (6 g, 17 mmol), MP-CNBH3 (30 g, 76.5 mmol), and cyclohexanecarboxaldehyde (12.4 mL, 102 mmol) via a procedure substantially analogous to Procedure C except that the SCX column is not used in purification. The di- HCl salt product (4.9 g, 65% yld) is isolated as a white solid via a procedure substantially analogous to Procedure D. MS(ES+)371.4(M+H)+free base.
Example 244
2-Isopropyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline: 2-Isopropyl-7- (3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 7-(3- piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (520 mg, 1.5 mmol), MP-CNBH3 (3.2 g, 7.5 mmol), and acetone (1.1 mL, 15 mmol) via a procedure substantially analogous to Procedure C except that the SCX column is not used in purification. The product (210 mg, 44% yld) is isolated as a clear oil. MS(ES+)317.2(M+H)+.
Example 275 l-[7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin-2-yl]-ethanone: A 5 mL CH2C12 solution of 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (175 mg, 0.5 mmol) and NEt3 (0.25 mL, 1J mmol) is stirred under N2, a 1 mL CH2C12 solution of acetyl chloride (0.043 mL, 0.6 mmol) is added, and reaction is stirred at room temp, for 5-6 hours. Reaction mixture is quenched with MeOH, concentrated and the residue is purified by chromatography (SCX-MeOH wash, elute 2M NH3/MeOH; then (SiO2; 0-10% MeOH/CH2Cl2/l%NH4OH gradient) to give the product (90 mg, 58% yld). MS(ES+)317.1(M+H)+
Example 257 [7-(3-Piperidin- 1 -yl-propoxy)-3 ,4-dihydro- lH-isoquinolin-2-yl]-thiophen-2-yl- methanone;
Procedure E: A 7 mL CHCl3/t-BuOH/MeCN (5:1:1) mixture of 7-(3-piperidin-l-yl- propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (256 mg, 0.74 mmol), resin bound DCC (1.1 g, 0.9 mmol), hydroxybenzotriazole (HOBt, 150 mg, 1.1 mmol), and thiophene-2-carboxylic acid (118 mg, 0.9 mmol) is shaken in a capped vial at room temperature for 48 hours. The reaction mixture is filtered and the resin beads washed twice alternately with MeOH, then CH2C12. The filtrate is concentrated and the residue is purified by chromatography (SCX-MeOH wash, elute 2M NH3/MeOH; then SiO2; 0-10% MeOH/CH2Cl2/l% NIJ4OH gradient) to give the pure free base as a solid (180 mg, 63% yld). MS(ES+) 385.1(M+H)+. A 3 mL dry MeOH solution of the free base (45 mg, 0.12 mmol) is stirred with IN HCl/Et2O (0.18 mL, 0.18 mmol) for 5 minutes, concentrated, triturated with Et2O, filtered, and dried in vacuo to the HCl salt as an off-white solid (46 mg). MS(ES+) 385. l(M+H)+free base.
Example 274
2-Dimethylamino-l-[7-(3-piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin-2-yl]- ethanone: 2-Dimethylamino-l-[7-(3-piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin- 2-yl]-ethanone is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride (175 mg, 0.5 mmol), PS-DCC (800 mg, 1.1 mmol), HOBt (80 mg, 0.77 mmol), NEt3 (0.21 mL, 1.5 mmol)and N,N-dimethylglycine (1.1 mL, 15 mmol) via a procedure substantially analogous to Procedure E except that PS-trisamine resin beads (700 mg, 2.6 mmol) is used in the work up to scavenge the excess HOBt and N,N-dimethylglycine. The free base product (35 mg, 19% yld) is isolated as an oil. MS(ES+)360.5(M+H)+.
Example 266 7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid isopropylamide: A 10 mL CH2C12 solution of 7-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-isoquinoline dihydrochloride (254 mg, 0.73 mmol), NEt3 (0.20 mL, 1.4 mmol), isopropyl isocyanate (192 mg, 2.2 mmol), and 4-dimethylaminopyridine (12 mg, 0.1 mmol) is stirred under N2, at room temperature for 18 hours. The reaction mixture is concentrated and the residue is purified by chromatography (SCX-MeOH wash, elute 2M NH3/MeOH; then SiO2; 0-10% MeOH/CH2Cl2/l%NH OH gradient) to give pure product (110 mg, 42% yld). MS(ES+) 360.2(M+H)+.
Example 249 2-Benzenesulfonyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline; Procedure F: A 5 L CH2C1 solution of 7-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-isoquinoline dihydrochloride (185 mg, 0.53 mmol) and NEt3 (0.22 mL,1.8 mmol) is stirred under N2, benzenesulfonyl chloride (0.08 mL, 0.62 mmol) is added, and reaction is stirred at room temperature for 5-6 hours. Reaction mixture is diluted with EtOAc, washed with saturated aqueous Na2CO3, and the aqueous layer back-extracted with EtOAc. The EtOAc extracts are combined, dried (Na2SO4), and concentrated. The residue is purified by chromatography (SiO2; 0-6% MeOH/CH2Cl2/l% NHiOH gradient) to give the product (160 mg, 73% yld). MS(ES+) 415.1(M+H)+ .
Example 268 7-(3-Piperidin-l-yl-propoxy)-2-(thiophene-2-sulfonyl)-l,2,3,4-tetrahydro-isoquinoline: 7-(3-Piperidin-l-yl-propoxy)-2-(thiophene-2-sulfonyl)-l,2,3,4-tetrahydro-isoquinoline is prepared from 7-(3-piperidin-l-yl-propoxy)-l ,2,3,4-tetrahydro-isoquinoline dihydrochloride (175 mg, 0.5 mmol), NEt3 (0.25 mL, 1.8 mmol), and thiophene-2- sulfonyl chloride (114 mg, 0.63 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the product (160 mg, 76% yld). MS(ES+)421.1(M+H)+.
Example 267
7-(3-Piperidin- 1 -yl-propoxy)-2-(propane-2-sulfonyl)- 1,2,3 ,4-tetrahydro-i soquinoline: 7- (3-Piperidin-l-yl-propoxy)-2-(propane-2-sulfonyl)-l,2,3,4-tetrahydro-isoquinoline is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (175 mg, 0.5 mmol), NEt3 (0.25 mL, 1.8 mmol), and isopropylsulfonyl chloride (0.07 mL, 0.60 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the product (93 mg, 49% yld). MS(ES+) 381.1(M+H)+.
Example 284 2-Methanesulfonyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline hydrochloride: 2-Methanesulfonyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline hydrochloride is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-i soquinoline dihydrochloride (183 mg, 0.52 mmol), NEt3 (0.25 mL, 1.8 mmol), and methanelsulfonyl chloride (0.05 mL, 0.66 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the free base product. A 5 mL dry MeOH solution of the free base (110 mg, 0.31 mmol) is stirred with IN HCl/Et2O (0.50 mL, 0.5 mmol) for 5 minutes, concentrated, triturated with Et2O, the Et2O decanted, and the residue dried in vacuo to give the HCl salt as a glass (118 mg, 65% yld). MS(ES+) 353.2(M+H)+free base.
Example 286 2-(4-Methoxy-benzenesulfonyl-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline hydrochloride: 2-(4-Methoxy-benzenesulfonyl-7-(3-piperidin-l-yl-propoxy)- 1,2,3,4-tetrahydro-isoquinoline hydrochloride is prepared from 7-(3-piperidin-l-yl- propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (150 mg, 0.43 mmol), NEt3 (0.21 mL, 1.5 mmol), and 4-methoxybenzenesulfonyl chloride (115 mg, 0.57 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the free base product. A 5 mL dry MeOH solution of the free base (131 mg, 0.29 mmol) is stirred with IN HCl/Et2O (0.40 mL, 0.4 mmol) for 5 minutes, concentrated, triturated with Et2O, filtered, and dried in vacuo to give the HCl salt (118 mg, 57% yld). MS(ES+) 445.2(M+H)+free base.
Example 277 l-{4-[7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-sulfonyl]-phenyl}- ethanone: l-{4-[7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-sulfonyl]- phenylj-ethanone is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride (175 mg, 0.5 mmol), NEt3 (0.25 mL, 1.8 mmol), and 4- acetylbenzenelsulfonyl chloride (131 mg, 0.60 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the product (85 mg, 37% yld). MS(ES+) 457.1(M+H)+.
Example 276 2-(4-n-Butyl-benzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline: 2-(4-n-Butyl-benzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-isoquinoline is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride (175 mg, 0.5 mmol), NEt3 (0.25 mL, 1.8 mmol), and 4-(n- butyl)benzenesulfonyl chloride (140 mg, 0.60 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the product (165 mg, 70% yld). MS(ES+)471.1(M+H)+.
Example 278 2-(4-Cyanobenzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline: 2-(4-Cyanobenzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l, 2,3,4- tetrahydro-isoquinoline is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride (175 mg, 0.5 mmol), NEt3 (0.25 mL, 1.8 mmol), and 4- cyanobenzenesulfonyl chloride (121 mg, 0.60 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the product (157 mg, 71% yld). MS(ES+) 440.1(M+H)+.
Example 287
4-[7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-sulfonyl]- benzamide: A 1.4 mL DMSO mixture of K2CO3 is stirred under N2, 2-(4-cyanobenzenesulfonyl)-7-(3- piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline (75 mg, 0.17 mmol) is added, 0.2 mL H2O added, followed by 30% H2O2 (1.4 mL, 12 mmol) and reaction is stirred at room temperature for 4 hours. The reaction mixture is diluted with MeOH, filtered, and the solids washed twice with MeOH. The filtrate is concentrated and the residue is purified by chromatography (SCX-MeOH wash, elute 2M NH3/MeOH; then SiO2; 0-10% gradient) to give the product as an off-white solid (26 mg, 26% yld). MS (ES+)458.2(M+H)+.
Example 285
2-(4-Fluoro-benzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline hydrochloride: 2-(4-Fluoro-benzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)- 1,2,3,4-tetrahydro-isoquinoline hydrochloride is prepared from 7-(3-piperidin-l-yl- propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (158 mg, 0.45 mmol), NEt3 (0.21 mL, 1.5 mmol), and 4-fluorobenzenesulfonyl chloride (115 mg, 0.55 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give 140 mg of free base product. The free base is converted to the HCl salt (150 mg, 71% yld) via a procedure substantially analogous Procedure D. MS (ES+)433.2(M+H)+free base.
Example 304
2-(2-Fluoro-benzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline: 2-(2-Fluoro-benzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-isoquinoline is prepared from 7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride (104 mg, 0.3 mmol), NEt3 (0.14 mL, 1.1 mmol), and 2- fluorobenzenesulfonyl chloride (80 mg, 0.41 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the free base product (85 mg, 66% yld) as an amber oil. MS (ES+) 433.2(M+H)+.
Example 305
2-(3-Fluoro-benzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro- isoquinoline: 2-(3-Fluoro-benzenesulfonyl)-7-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-isoquinoline is prepared from 7-(3-piperidin-l-yl-propoxy)- 1,2,3, 4-tetrahydro- isoquinoline dihydrochloride (104 mg, 0.3 mmol), NEt (0.14 mL, 1.1 mmol), and 3- fluorobenzenesulfonyl chloride (80 mg, 0.41 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the free base product (90 mg, 70% yld) as an off-white solid. MS (ES+) 433.2(M+H)+.
6-OH tetrahydroisoquinoline series
6-hydroxy-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester is prepared by the procedures similar to those described in Selnick, H.G.; Smith, G. R.; Tebben, A. J.; Synth. Commun. 1995, 25, 3255-3262.
Example 127 6-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester: To a round-bottom flask, equipped with stir bar and septum, is placed 6-hydroxy- 3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester (1 g, 4.01 mmol), KI (599 mg, 4.01 mmol) and NaH (162 mg, 95%dry, 6.42 mmol). Then, dry DMF (20 mL, 0.5 M) is added via syringe followed by N-(3-chloropropyl)piperidine (0.85 mL, 5.2 mmol). The reaction is allowed to stir at 70 degrees overnight. In the morning, the reaction is quenched with water, extracted into EtOAc (3 x 20 mL) and dried over brine. Column chromatography in 9:1 DCM:MeOH affords 6-(3-piperidin-l-yl-propoxy)-3,4-dihydro- lH-isoquinoline-2-carboxylic acid tert-butyl ester an orange oil (1 g, 67%). Mass sec hit M+l, 375; LCMS >95% @ 230 nm and ELSD.
In a similar manner the Examples 35, 139, and 164 are prepared:
Example 35
6-(3-Dimethylamino-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester; M+l 335
Example 139 6-[3-(2-Methyl-piperidin-l-yl)-propoxy]-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester; M+l 389
Example 164
6-(2-Piperidin-l-yl-ethoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester; M+l 361.
Example 128
6-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride: To a round-bottom flask, equipped with stir bar and septum, is placed 6-(3-piperidin-l-yl- propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester (1 g, 2.6 mmol), DCM (20 L) and 4M HCl/dioxane (5 L). The reaction is allowed to stir at room temperature for 3 h. After this time, the reaction is concentrated, dissolved in MeOH and concentrated again affording 6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride as a white solid (800 mg, 87%). Mass spec hit M+l, 275; LCMS >95% @ 230 nm and ELSD. In a similar manner the Examples 40, 140, and 165 are prepared:
Example 40 Dimethyl-[3-(l,2,3,4-tetrahydro-isoquinolin-6-yloxy)-propyl]-amine dihydrochloride; M+l 235.
Example 140 6-[3-(2-Methyl-piperidin-l-yl)-propoxy]-l,2,3,4-tetrahydro-isoquinoline dihydrochloride; M+l 289.
Example 165 6-(2-Piperidin-l-yl-ethoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride; M+l 261.
Example 129 2-Ethyl-6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline: To a 25 mL round- bottom flask is placed 6-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (700 mg, 2.01 mol), MP-CNBH3 (2.5 g, 6.05 mmol, 2.42 mmol/g) and DCM/MeOH (9mL/lmL). Then, acetaldehyde is added (0.7 mL, 12 mmol) and the reaction is allowed to stir overnight. The reaction is then filtered, washed with DCM/MeOH and concentrated. Column chromatography in 9:1 DCMMeOH affords 2- ethyl-6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline (493 mg, 71%) of a viscous oil. Mass spec hit M+l, 303; LCMS >95% @ 230 nm and ELSD. Array synthesis followed this general procedure in 4 mL vials to make the following compounds:
Example 250 2-Ethyl-6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride: 2-Ethyl-6- (3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline (5.12g, 16.9 mmol) is dissolved in MeOH (50 mL), and IM HCl in ether is added dropwise (37.2 mL, 37.2 mmol) and the mixture is stirred for 10 minutes and concentrated to give the dihydrochloride salt as a white solid (6.0 g, 93%).
Example 143 2-Isopropyl-6-[3-(2-methyl-piperidin-l-yl)-propoxy]-l,2,3,4-tetrahydro-isoquinoline: To a flask equipped with a stir bar is placed 6-[3-(2-Methyl-piperidin-l-yl)-propoxy]-l,2,3,4- tetrahydro-isoquinoline dihydrochloride (300 mg, 0.83 mmol), acetone (excess), NaCNBH3 (155 mg, 2.5 mmol) in MeOH (8 mL) and the mixture stirred at room temperature for 2h. The reaction mixture is diluted with water, and extracted with CH2C12. The organic phase is dried over Na2SO4 and concentrated. M+l 331, LCMS
>98% @ 230 nm and ELSD.
In a similar manner Example 138 is prepared:
Example 138
2-Isopropyl-6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline; M+l 317, LCMS 100% @ 230 nm and ELSD.
Example 162
[6-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin-2-yl]-thiazol-2-yl-methanone: To a 4 mL vial is placed 6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (28 mg, 0.08 mmol), resin-bound DCC (134 mg, 0.16 mmol, 1.2 mmol/g), HOBt (16 mg, 0.12 mmol), pyrazole carboxylic acid (13 mg, 0.1 mmol) and a 5:1:1 mixture of CHCl3:CH3CN:tBuOH. The vial is agitated by means of a lab quake shaker overnight. In the morning, PS-trisamine (134 mg, 0.4 mmol, 3.0 mmol/g) is added and the reaction is again allowed to rotate overnight to scavenge excess carboxylic acid and HOBt. Filtration, washing with DCM/MeOH and concentration affords a orange foam. Filtration through a short pipet column provides 24 mg (80%) of [6-(3- piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin-2-yl]-thiazol-2-yl-methanone as an orange solid. Mass spec hit M+l, 386; LCMS >95% @ 230 nm and ELSD. Array synthesis follows this general procedure in 4 mL vials to make the following examples:
Example 178 6-(2-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid isopropylamide: To a 4 mL vial is placed 6-(3-piperidin-l-yl-propoxy)-l,2,3,4- tetrahydro-isoquinoline dihydrochloride (25.0 mg, 0.07 mmol), resin-bound Hunigs base (81 mg, 0.29 mmol, 3.54 mmol/g), resin bound DMAP (catalytic), and dry CH2C12 and isopropyl isocyanate (16 DL, 0.18 mmol). The vial is agitated by means of a lab quake shaker overnight. In the morning, PS-trisamine (120 mg, 0.36 mmol, 3.0 mmol/g) is added and the reaction again allowed to rotate for 4 hours to scavenge excess isocyanate. Filtration, washing with CH2C12 and concentration afforded the desired urea. M+l 360. In a similar manner Examples 179 is prepared:
Example 179 6-(2-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid cyclohexylamide; M+l 400.
Example 79 [3-(2-Methanesulfonyl-l,2,3,4-tetrahydro-isoquinolin-6-yloxy)-propyl]-dimethyl-amine: To a 4 mL vial is placed Dimethyl-[3-(l,2,3,4-tetrahydro-isoquinolin-6-yloxy)-propyl]- amine (24.0 mg, 0.1 mmol), resin-bound DIEA (58 mg, 0.2 mmol, 3.54 mmol/g), MsCl (12 DL, 0.15 mmol) and dry CH2C12 (2 mL). The vial is allowed to rotate overnight. In the morning, PS-trisamine (136 mg, 0.41 mmol, 3.0 mmol/g) is added and the reaction again allowed to rotate for 4 hours to scavenge excess MsCl. Filtration, washing with CH2C12 and concentration affords the desired urea LCMS >99% @ 230 nm and ELSD, M+l 360.
Example 302 2-Benzenesulfonyl-6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline: 2- Benzenesulfonyl-6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 6-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (330 mg, 0.95 mmol), NEt3 (0.48 mL, 3.5 mmol), and benzenesulfonyl chloride (0.15 mL, 1.17 mmol) via a procedure substantially analogous to Procedure F except that an additional SCX column purification step is performed to give the product as a white solid (250 mg, 63% yld). MS(ES+) 415.3(M+H)+.
5-OH tetrahydroisoquinoline series
5-Hydroxy-3,4-dihydro-l-H-isoquinoline-2-carboxylic acid tert-butyl ester is prepared by the procedures similar to those described in Durand S.; Lusinchi, X.; Moreau, R. C. Bull. Soc. Chim. France 1961, 207, 270; and Georgian, V.; Harrison, R. J.; Skaletzky, L. L.; / Org Chem 1962, 27, 4571.
Example 290 5-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester is prepared from 5-Hydroxy-3,4-dihydro-l-H-isoquinoline-2-carboxylic acid tert- butyl ester (5.69 g, 22.8 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane. Following aqueous workup, the crude material is purified by flash chromatography [Biotage 65M SiO2, elute 10% (25/5/1 CHC /MeOH/NH-OH) / 90% (10% MeOH/CHCl3)] to give the title compound (5.2 g, 61%). MS (ES+) 375.3
Example 291 5-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt is prepared from 5-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester (4.0 g, 10.7 mmol) in a manner substantially analogous to Procedure B to give the title compound as an off-white solid (3.47 g, 93%). MS (ES+) 275.2
Example 309 [5-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin-2-yl]-thiophen-2-yl- methanone is prepared from 5-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (0.256 g, 0.74 mmol) in a manner substantially analogous to Procedure E to give the title compound as an off-white solid (0.109 g, 38%). MS (ES+) 415.2
Example 294
2-Benzenesulfonyl-5-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 5-(3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (150 mg, 0.43 mmol) via a procedure substantially analogous to Procedure F to provide the title compound as an off-white solid (54 mg, 30%). MS (ES+) 385.2
Example 306 2-Ethyl-5-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 5- (3-Piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (375 mg, 1.1 mmol) in a manner substantially analogous to Procedure C to give the title compound as a yellow oil (49 mg, 15%). MS (ES+) 303.3
Example 313 2-Cyclohexylmethyl-5-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 5-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (350 mg, 1.0 mmol) in a manner substantially analogous to
Procedure C to give the title compound as a yellow oil (0.142 mg, 38%). MS (ES+) 371.4
8-OH tetrahydroisoquinoline series
8-Methoxy-l,2,3,4-tetrahydro-isoquinoline is prepared according to Shanker, P. S.; Subba Rao, G. S. R. Indian I. of Chemistry section B 1993, 32B, 1209-1213.
8-Hydroxy-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester: To a mixture of 8-mefhoxy-l,2,3,4-tetrahydro-isoquinoline (2.54 g, 15.6 mmol) in CH2C12 (60 mL) at - 78 °C is added a solution of boron tribromide in CH2C1 (1 M, 52 mL, 52 mmol) dropwise over approximately 20 minutes. The cooling bath is removed, and the mixture is warmed to room temperature. After 4 h, the reaction is carefully quenched with ice. EtOAc and water is added, and the mixture is stirred overnight. The phases are separated, and 5 N NaOH solution is added to the aqueous phase until pH is basic. Dioxane (250 mL) and di-tert-butyl dicarbonate (6.78 g, 31 mmol) is added, and reaction mixture is stirred at room temperature overnight. EtOAc is added, and the phases are separated. The aqueous phase is extracted with EtOAc (IX), and the combined organic phase is washed with brine and dried (MgSO4). After filtration, the solvent is removed in vacuo to provide the title compound (4.84 g) that is used without purification. MS (ES-) 248.2.
Example 307
8-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester is prepared from 8-hydroxy-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert- butyl ester (0.84 g, 3.4 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane. Following aqueous workup, the crude material is purified by chromatography [SCX-MeOH wash, elute 2M NH3/MeOH then Biotage 40s SiO2, elute 10% (25/5/1 CHCl-j/MeOH/NHiOH) / 90% (10% MeOH/CHCl3)] to give the title compound (0.61 g, 48%). MS (ES+) 375.3.
Example 308
8-(3-Piperi din- 1 -yl-propox y)-l, 2,3, 4-tetrahydro-isoquinoline dihydrochloride salt is prepared from 8-(3-piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester (3.09 g, 8.25 mmol) in a manner substantially analogous to Procedure B to give the title compound as an off-white solid (2.63 g, 85%). MS (ES+) 275.3
Example 309 2-Cyclohexylmethyl-8-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 8-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (0.375 g, 1.1 mmol) in a manner substantially analogous to Procedure C to give the title compound as a yellow oil (0.195 g, 48%). MS (ES+) 371.4
Example 310 2-Ethyl-8-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 8- (3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (0.375 g, 1.1 mmol) in a manner substantially analogous to Procedure C to give the title compound as a yellow oil (0.124 g, 37%). MS (ES+) 303.3.
Example 311
2-Benzenesulfonyl-8-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline is prepared from 8-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (300 mg, 0.86 mmol) via a procedure substantially analogous to Procedure F to provide the title compound as an off-white solid (0.22 g, 63%). MS (ES+) 415.3.
Example 312 [8-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-lH-isoquinolin-2-yl]-thiophen-2-yl- methanone: To a mixture of 8-(3-piperidin-l-yl-propoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride salt (300 mg, 0.86 mmol) and NEt3 (0.36 mL, 2.6 mmol) in CH2C12 (10 mL) is added 2-thiophene carbonyl chloride (0.10 mL, 0.95 mmol). After stirring at room temperature overnight, the mixture is partitioned between EtOAc and water. The organic phase is washed with brine, dried (MgSO4), and concentrated. The residue is purified by flash chromatography [Biotage 40S SiO2, elute 20% (90/10/1 CH2Cl2/MeOH/NH4OH) / 80% CH2C12 to 100% (90/10/1 CH-CyMeOH/NFUOH)] to yield the title compound as a yellow oil (0.181 g, 55%). MS (ES+) 385.3.
Example 206 6-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-2H-isoquinolin-l-one is prepared from 6- hydroxy-3,4-dihydro-2H-isoquinolin-l-one (CAS Registry Number 22245-98-3) (0.5 g, 2.9 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane. Following aqueous workup, the crude material is purified by flash chromatography (Biotage 40M SiO2, elute 90/10/1 CH2Cl2/MeOH/NH4OH) to give the title compound as a white solid (0.516 g, 61%). MS (ES+) 289.1
Example 207 7-(3-Piperidin-l-yl-propoxy)-3,4-dihydro-2H-isoquinolin-l-one is prepared from 7- hydroxy-3,4-dihydro-2H-isoquinolin-l-one (CAS Registry Number 22246-05-5) (1.43 g, 8.76 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane. Following aqueous workup, the crude material is purified by flash chromatography (Biotage 40M SiO2, elute 90/10/1 to give the title compound as a white solid (1.11 g, 44%). MS (ES+) 289.1
Example 205 7-(3-Pyrrolidin-l-yl-propoxy)-3,4-dihydro-2H-isoquinolin-l-one is prepared from 7- hydroxy-3,4-dihydro-2H-isoquinolin-l-one (0.48 g, 2.94 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane and l-(3-Chloro- propyl)-pyrrolidine is used instead of N-(3-chloropropyl)pi peri dine. Following aqueous workup, the crude material is purified by flash chromatography (Biotage 40M SiO2, elute 90/10/1 CH2Cl2/MeOH/NH4OH) to give the title compound as an off-white solid (0.17 g, 21%). MS (ES+) 275.1
2-Ethyl-6-hydroxy-3,4-dihydro-2H-isoquinolin-l-one:
To a mixture of 6-methoxy-3,4-dihydro-2H-isoquinolin-l-one (0.30 g, 1.69 mmol) in THF (10 mL) is added sodium hydride (60% mineral oil suspension, 100 mg). The suspension is heated at reflux for 1 h, and cooled to room temperature. Ethyl iodide (1.4 mL, 17 mmol) is added, and the mixture is stirred at room temperature overnight. The mixture is partitioned between EtOAc and water. After the aqueous phase is extracted with EtOAc (2x), the combined organic phase is washed with brine and dried (MgSO4). After removal of the solvent, the residue is purified by flash chromatography (Biotage 40M SiO2, elute 45% EtOAc:hexane - 50% EtOAc:hexane, linear gradient) to yield 2- ethyl-6-methoxy-3,4-dihydro-2H-isoquinolin-l-one as a colorless oil (0.275 g, 78%). The material is dissolved in CH2C12 (10 mL) and cooled to -78 °C. To the cooled mixture is added a solution of boron tri bromide (1 M, 4.7 mL, 4.7 mmol) in CH2C12. After 0.5 h, the temperature is warmed to 0 °C and stirred for 3 h. After the reaction is carefully quenched with ice, EtOAc and water is added, and the mixture is vigorously stirred overnight. The phases are separated, and the organic phase is extracted with EtOAc (2x). The combined organic phase is washed with brine and dried (MgSO4). The solvent is removed in vacuo, and the residue is purified by chromatography (Varian 10 g SiO2 cartridge, elute 60% EtOAc:hexane) to provide 2-ethyl-6-hydroxy-3,4-dihydro-2H- isoquinolin-1-one (0.209 g, 82%). MS (ES+) 192.0
Example 265 2-Ethyl-6-(3-piperidin-l-yl-propoxy)-3,4-dihydro-2H-isoquinolin-l-one is prepared from 2-Ethyl-6-hydroxy-3,4-dihydro-2H-isoquinolin-l-one (0.192 g, 1.0 mmol) in a manner substantially analogous to Procedure A except DMF is used in place of dioxane. Following aqueous workup, the crude material is purified by chromatography [Varian 10 g SiO2 cartridge, elute 10% (25/5/1 CHC /MeOH/NHtOH) / 90% (10% MeOH/CHCl3)] to obtain the title compound as a waxy off-white solid (77 mg, 24%). MS (ES+) 317.1
Example 303
[3-Fluoro-4-(3 -piperidin- 1 -yl-propoxy)-phenyl] -(2-pyrrolidin- 1 -ylmethyl-pyrrolidin- 1 - yl)-methanone: General Procedure G: A mixture of (3-Fluoro-4-hydroxy-phenyl)-(2-pyrrolidin-l- ylmethyl-pyrrolidin-l-yl)-methanone (0.193 g, 0.66 mmol), Cs2CO3 (0.43 g, 1.32 mmol),
KI (55 mg, 0.33 mmol), and N-(3-chloropropyl)piperidine (3.9 g, 24 mmol) in DMF (5 mL) is heated at 90 °C overnight. The mixture is partitioned between EtOAc and water.
The phases are separated, and the aqueous phase is extracted with EtOAc (2x). The combined organic phase is washed with brine, dried (MgSO4), and concentrated in vacuo.
The residue is purified by chromatography [SCX-MeOH wash, elute 2M NH3/MeOH; then Biotage 12M SiO2, elute 10% (25/5/1 CHCls/MeOH/NH OH) / 90% (10%
MeOH/CHCl3)] to give the title compound as a yellow oil (0.105 g, 38%). MS (ES+)
Example 240 { l-[4-(3-Piperidin-l-yl-propoxy)-phenyl]-cyclopropyl}-carbamic acid benzyl ester is prepared from [l-(4-Hydroxy-phenyl)-cyclopropyl]-carbamic acid benzyl ester (1.21 g, 4.28 mmol), Cs2CO3 (2.78 g, 8.55 mmol), KI (71 mg, 0.43 mmol), and N-(3- chloropropyl)piperidine (0.86 g, 5.34 mmol) in dioxane (50 mL) in a manner substantially analogous to Procedure A to give the product( (1.16 g, 66%). MS (ES+) 409.3.
Example 241 l-[4-(3-Piperidin-l-yl-propoxy)-phenyl]-cyclopropylamine:
{ l-[4-(3-Piperidin-l-yl-propoxy)-phenyl]-cyclopropyl}-carbamic acid benzyl ester (1.08 g, 2.65 mmol) is dissolved in ethanol (50 mL), and 10% Pd/C is added (200 mg). The mixture was stirred under a balloon on hydrogen for 3 hours. The reaction mixture was stirred through a plug of silica gel to give the desired compound. HRMS 275.2123 (M+H)+.
Example 247
2-Morpholin-4-yl-N-{ l-[4-(3-piperidin-l-yl-propoxy)-phenyl]-cyclopropyl}-acetamide: l-[4-(3-Piperidin-l-yl-propoxy)-phenyl]-cyclopropylamine (0.195 g, 0.72 mmol) and morpholin-4-yl-acetic acid (0.125 g, 0.86 mmol) are dissolved in DMF, and diisopropylethylamine added (0.15 mL), followed by EDC (0.165 g, 0.86 mmol) and HOBt (0.116 g, 0.86 mmol). The reaction mixture was stirred overnight at room temperature. The residue is purified by chromatography [SCX-MeOH wash, elute 2M NH3/MeOH; then Biotage 12M SiO2, elute 10% (25/5/1 CHCl3/MeOH/NHtOH) / 90% (10% MeOH/CHCl3)] to give the title compound as a yellow oil. HRMS 402.2765 (M+H)+.
Example 316
7-(4-Piperidin-l-yl-butoxy)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester: A 20 mL DMF mixture of 7-(4-chloro-butoxy)-3,4-dihydro-l-H-isoquinoline-2- carboxylic acid tert-butyl ester(1.0 g, 3 mmol), piperidine (0.75 mL, 7.5 mmol), and KI (1.0 g, 6 mmol) is stirred at 50 °C under N2 for four hours, then at room temperature for
16 hours. The reaction mixture is directly purified by chromatography (SCX-MeOH wash, elute 2M NH3/MeOH; then SiO2; 0-6% MeOH/CH2Cl2/l%NH4OH gradient)to give the free base (700 mg, 60% yld). MS(ES+)389.3 (M+H)+free base.
Example 314 7-(4-Piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride: 7-(4- Piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride is prepared from
7-(4-chloro-butoxy)-3,4-dihydro-l-H-isoquinoline-2-carboxylic acid tert-butyl ester(600 mg, 1.5 mmol) and 4N HCl/ dioxane (2.5 mL, 10 mmol) base in a manner substantially analogous to Procedure B to give the product(490 mg, 90% yld). MS(ES+)389.3
(M+H)+free Cl
Example 315
2-Ethyl-7-(4-piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride: 2- Ethyl-7-(4-piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride is prepared from 7-(4-piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride (252 mg, OJ mmol), and acetaldehyde (0.40 mL, 7 mmol) in a manner substantially analogous to Procedure C to give the dihydrochloride product as an off white solid(125 mg, 70% yld). MS(ES+)317.2(M+H)+free base.
Example 317
2-Cyclohexylmethyl-7-(4-piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro-isoquinoline dihydrochloride: 2-Cyclohexylmethyl-7-(4-piperidin-l-yl-butoxy)-l,2,3,4-tetrahydro- isoquinoline dihydrochloride is prepared from 7-(4-piperidin-l-yl-butoxy)-l, 2,3,4- tetrahydro-i soquinoline dihydrochloride (175 mg, 0.48 mmol), and cyclohexanecarboxaldehyde (0.35 mL, 2.9 mmol) in a manner substantially analogous to
Procedure C to give the dihydrochloride product as an off white solid(105 mg, 62% yld). MS(ES+)385.3(M+H)+ free base.
Example 208 [3-(3-Piperidin-l -yl-propox y)-benzyl]-(3-pyrrolidin-l-yl-propyl)-amine: The reductive amination is run with 3-(3-piperidin-l-yl-propoxy)-benzaldehyde (1 g, 4 mmol) and ), 3- pyrrolridin-1-yl propylamine (1 mL, 8 mmol), and MP-CNBH3 resin(4.5g, 10.4 mmol)via a procedure substantially analogous to [2-(3-piperidin-l-yl-propoxy)-benzyl]-(3- pyrrolidin-l-yl-propyl)-amine to give the product as a yellow oil(818 mg, 58 % yld). MS(ES+)360.3(M+H)+free base.
Example 202 [4-(4-Piperidin-l-yl-butoxy)-benzyl]-(2-pyrrolidin-l-yl-ethyl)-amine: An 8 mL DMF solution of [4-(4-bromo-butoxy)-benzyl]-(2-pyrrolidin-l-yl-ethyl)-amine (307 mg, 0.86 mmol) and piperidine (0.22 mL, 2.2 mmol) is stirred at 90 °C for six hours under N2. The reaction mixture is cooled, diluted with CH2C12, filtered, washed with brine, dried (Na2SO4), and concentrated. The residue is purified by chromatography (SiO2; 0-6% MeOH/CH2Cl2/l%NH4OH gradient) to give the product (40 mg, 12% yld). MS(ES+)360.4(M+H)+ free base.
Example 236 N-(2-Piperidin-l-yl-ethyl)-4-(3-piperidin-l-yl-propoxy)-benzamide is prepared according to general procedure A from 4-Hydroxy-N-(2-piperidin-l-yl-ethyl)-benzamide (CAS
Registry 106018-38-6) (0.27 g, 1.1 mmol) to give the title compound as a white solid (77 mg, 19%). MS (ES+) 374.3
Example 237 2-Fluoro-N-(2-piperidin-l-yl-ethyl)-4-(3-piperidin-l-yl-propoxy)-benzamide: To a mixture of 2-Fluoro-4-(3-piperidin-l-yl-propoxy)-benzoic acid (70 mg, 0.25 mmol) and l-(2-aminoethyl)piperidine (45 DL, 0.3 mmol) in DMF (5 mL) was added EDC (58 mg, 0.3 mmol), HOBT (40 mg, 0.3 mmol), and diisopropylethyl amine (52 Dl, 0.3 mmol). The mixture was stirred at room temperature overnight. The mixture was partitioned between EtOAc and water. The organic phase was washed with brine, dried (MgSO4), and concentrated. The residue was purified by flash chromatography (Biotage 12 M, elute 90/10/1 CH2Cl2/MeOH/NH4OH) to yield the title compound. MS (ES+) 392.3
Example 264 3-Fluoro-N-(2-piperidin-l-yl-ethyl)-4-(3-piperidin-l-yl-propoxy)-benzamide is prepared from 3-Fluoro-4-hydroxy-N-(2-piperidin-l-yl-ethyl)-benzamide (0.1 g, 0.38 mmol) by general procedure A to yield the title compound as an off-white solid (80 mg, 54%). MS (ES+) 392.2
Example 256
(2-Morpholin-4-yl-ethyl)-[4-(3-piperidin-l-yl-propoxy)-benzyl]-amine dihydrochloride: The dihydrochloride salt was prepared from (2-morpholin-4-yl-ethyl)-[4-(3-piperidin-l- yl-propoxy)-benzyl]-amine (0.307 g) by dissolving in THF (6 mL) and adding a solution of HCl in Et2O (1 M, 0.85 mL). Additional Et2O was added until the mixture was cloudy, and the mixture was allowed to stand at 0 °C overnight. The white solid was collected by filtration to give the dihydrochloride salt. Anal. Calculated for C2]H35N3O2 2 HCl: C, 58.06; H, 8.58; N, 9.67; Cl, 16.32. Found: C, 58.0; H, 8.51; N, 9.57; Cl, 16.99.
PyBOP, Et3N JQTVJ.
(1)R; Yield =69% (2)S; Yield =54%
LiΛIII4
Synthesis of (1) 1.50g of ®(+)-l-(4-methoxyphenyl) ethylamine (lO.Ommol), 2.06g of N, N- Dimethylglycine (20.0mmol) and 2.58g of N, N-Di-isopropylethylamine (20.0mmol) were dissolved in 50ml of CH2C12 and 6.78g of PyBOP (13.0mmol) was added to the mixture. The reaction mixture was stirred at room temperature for 4h. The reaction mixture was diluted with 20ml of CH2C12 and washed with brine, 0.1N HI, brine satNaHCO3 and brine. The separated organic layer was dried over NaSO4 and evaporated. The crude product was applied to short silica-gel column chromatography (CH2C12 - CH2C12 : 2M NH3 in MeOH = 20:1) and pure product was recrystalized from Et2O/ CH2C12. White powder. 1.62g(69%). C/MS : m z 237(M+1)
Synthesis of (2)
This compound was synthesized according to the method described in the preparation of (1). Synthesis of (3) 500mg of compound (1) (2.12mmol) was dissolved in 5.0ml of CH2C12 and cooled to 0 °C. 10.0ml of BBr3 1.0M in CH2C12 (lOmmol) was added slowly and stirred at 0°C for lh. MeOH was added to quench the reaction and 4.0ml of 5NaOHaq. was added. The mixture was stirred at 0°C for lOmin. CH C12 layer was separated. The water layer was acidified slowly PH=14- 2 and extracted with CH2C12 for each step. The water layer was concentrated in vacuo, filtered off NaCl. The filtrate was made to PH=10 stepwise and extracted with CH2C12 each step. All of these extractions were combined together, dried over NaSO4 and evaporated to give the product 301mg (64%). LC/MS : m/z 223(M+1)
Synthesis of (4) This compound was synthesized according to the method described in the preparation of (3).
Synthesis of (5)
52mg of compound (3) (0.23mmol), 57mg of 3-diethylaminopropanol (0.28mmol) and 73mg of Triphenylphosphine (0.28mmol) were dissolved in 2.0ml of dry THF. The air was replaced to N2 gas. 37mg of Diisopropyl-azodicarboxylate (0.28mmol) in 0.5ml of THF was added to this reaction mixture and stirred at room temparature for overnight. The reaction mixture was concentrated and applied to SCX column, washed by MeOH. The crude product was eluted with 2M NH3 in MeOH. This crude product was applied to silica-gel column chromatography (CH2C1 : 2M NH3 in MeOH = 20:1) to give the product. 48mg (62%). LC/MS : m/z 336(M+1)
Synthesis of (6)
This compound was synthesized according to the method described in the preparation of (5).
Synthesis of (7) 3.0ml of Litium aluminium hydride l.OM in THF (3.0mmol) was placed in flask and the air was replaced to N2gas. 43mg of compound (5) (0.13mmol) in 2.0ml of THF was added slowly into the flask and stirred under reflux for 2h. The reaction mixture was allowed to cool to room temperature and water was added to quench the reaction. The organic layer was decanted. The water layer was extracted with CH2C12 (3 times) and all organic layers were combined together. This solution was dried over NaSO4 and evaporated. The crude product was applied to silica-gel column chromatography (CH2C12: 2M NH3 in MeOH = 20:1) to give the product. 19mg (46%). LC/MS : m/z 322(M+1)
Synthesis of (8) This compound was synthesized according to the method described in the preparation of (7).
Synthesis of (10) lOOmg of compound (9) (0.50mmol) and 116mg of (R)(-)-l-(2- pyrrolidinylmethyl)pyrrolidine (0J5mmol) were dissolved in 5.0ml of 5%AcOH in CH2C12 and 310mg of MP-cyanoborohydride (mmo/g =2.42, 0J5mmol) was added in the reaction vial. The vial was capped by Teflon cap and shaken at 60°C for overnight. The reaction mixture was filtered and the filtrate was concentrated under N2 gas. The crude product was applied to silica-gel column chromatography (CH2C12 : 2M NH3 in MeOH = 20:1) to give the product. 143mg (85%). LC/MS : m/z 337(M+1)
Synthesis of Example 261 65 mg of compound (10) (0.19mmol) and 50mg of piperidine (0.58mmol) were put into 4.0ml vial and 2.0ml of THF and lOmg of Nai were added to the vial. The vial was capped by Teflon cap and heated at 100°C for 3days. The reaction mixture was concentrated under N2gas and applied to silica-gel column chromatography (CH2C12 : 2M NH3 in MeOH = 20:1) to give the product. 38mg (51%). LC/MS : m z 386(M+1)
Synthesis of (15) 813mg of compound (14) (98536) (3.8mmol) was dissolved in 5.0ml of thionyl chloride and stirred at 70°C for lh under N2 gas. The excess acid chloride was removed in vacuo. The residue was dissolved in 1.0ml of CH2C12 to make acid chloride solution. 643mg of (S)(+)-l(2-pyrrolidinylmethyl)pyrrolidine (4.17mmol) and 421mg of triethylamine (4.17mmol) were dissolved in 10ml of CH2C12 and cooled to 0°C. Acid chloride solution was added to this mixture at 0°C and stirred at room temperature for 2h. The reaction mixture was diluted with CH2C1 and washed by brine. The crude product was applied to silica-gel column chromatography (CH2C12 : 2M NH3 in MeOH = 10:1) to give the product. 1.13g (85%) LC/MS : m/z 351(M+1)
Synthesis of Example 209 This compound was synthesized according to the method described in the preparation of Example 261.
(17) (18) Y=17% Synthesis of (18) 1.17g of Na(51mmol) was dissolved in 200ml of MeOH and 6.48g of methyl p-hydroxy benzoate(17) (42.5mmol) was added followed by 20.52g of 1-bromo 4-chlorobutane (119.6mmol). The reaction mixture was stirred at room temperature for 2h and stirred at 60°C for lh. Almost of MeOH was removed in vacuo. The residue was dissolved in water and acidified by cHCl to PH=1.0 and extracted with CH2C12. The separated organic layer was dried over NaSO4 and evaporated. The crude product was applied to silica-gel column chromatography (CH2C12 : 2M NH3 in MeOH = 20:1) to give the product. 1.64g (17%). NMR (DMSO); 7.84(d, 2H, J=5.9Hz), 6.91( d, 2H, J=5.9Hz), 4.02(t, 2H, J=5.8Hz), 3.69(t, 2H, J=6.4Hz), 1.85( m, 4H)
NaOHaq.
(19)
(20) Yield = 77%
Synthesis of (20) 1.14g of compound (19) (4.44mmol) was dissolved in 15ml of MeOH and 10ml of 5N NaOHaq. was added. The reaction mixture was stirred at room temperature for overnight. The reaction mixture was evaporated. The residue was dissolved in water and acidified by cHCl to PH=1.0. This solution was extracted with CH2C12, dried over NaSO4 and evaporated. The pure product was recrystalized from Hexane/ CH2C12. 829mg (77%) NMR (DMSO); 8.05(d, 2H, J=8.9Hz), 6.93( d, 2H, J=8.9Hz), 4.05(t, 2H, J=6.3Hz), 3.57(t, 2H, J=6.8Hz), 1.86( m, 4H), 1.65(m, 2H)
^-DCC, HOBt
Example 131 — Trisamine To a 4 mL vial was placed 101 (28.5 mg, 0.1 mmol), resin-bound DCC (170 mg, 0.16 mmol, 0.94 mmol/g), HOBt (16 mg, 0.12 mmol), amine (13 uL, 0.08 mmol) and a 5:1:1 mixture of CHCl3:CH3CN:tBuOH. The vial was agitated by means of a lab quake shaker overnight. In the morning, PS-trisamine (134 mg, 0.4 mmol, 3.0 mmol/g) was added and the reaction again allowed to rotate overnight to scavenge excess carboxylic acid and
HOBt. Filtration, washing with DCM/MeOH and concentration afforded a orange foam.
Filtration through a short pipet column provided 25 mg (83%) of an yellow solid, 629304.
Mass spec hit M+l, 386; LCMS >95% @ 230 nm and ELSD. A substantially analogous procedure was employed for the array synthesis of Examples:
-[4-(3-Piperidin-1 -yl-propoxy)-phenyl]-butan-1 -one
To a 20 mL vial was placed keto-phenol (500 mg, 3 mmol), CsCO3 (1.98 g, 6 mmol), KI
(454 mg, 3 mmol) and chloropropylpiperdine (64 mg, 3.3 mmol). Dioxane added and the reaction was heated to 90 degrees overnight on a J-KEM heater/shaker block. The reaction was then quenched with water, extracted into DCM and dried over Na2SO4.
The material was purified by Biotage utilizing 4:1 EtOAc:MeOH to afford (201) as a orange oil (880 mg, 99%). Mass spec hit M+l, 290; LCMS >95% @ 230 nm and ELSD.
Example 94 Example 94, and 192.
To a 20 mL vial was placed (102) (300 mg, 1 mmol), diamine (120 mg, 1.14 mmol), MP- CNBH3 (2.4 g, 6.22 mmol) and a 9:1 CHCl3:HOAc solution. The reaction was heated to
50 degrees overnight on a J-KEM heater/shaker block. The reaction was filtered, washed with DCM/MeOH. The material was then subjected to preparative HPLC purification to afford 29 mg (3%) of analytically pure example 94. as a white solid. Mass spec hit M+l,
362; LCMS >98% @ 230 nm and ELSD. Example 192 can be made by a substantially analogous procedure, Observed mass 360. The following examples are made by a substantially analogous procedure:
Product Name Examole (M+1 ) Λ/-[6-(3-Dιmethylamιno-propoxy)-1 ,2,3,4-tetrahydro- „ . 320 naphthalen-1 -yl]-W,Λ/-dιmethyl-ethane-1 ,2-dιamιne
Λ/-[6-(3-Dιmethylamιno-2-methyl-propoxy)- 85 246 M-87
-N X -0 .C 1,2,3,4-tetrahydro-naphthalen-1-yl]- /V,/V-dιmethyl-ethane-1 ,2-dιamιne
Λ/,Λ/-Dιmethyl-/V-[6-(1-methyl-pιperιdιn-3- 86 346 ylmethoxy)-1 ,2,3,4-tetrahydro-naphthalen-
N' ^0 CO 1 -yl]-ethane-1 ,2-dιamιne
W-{1 -[4-(3-Dιmethylamιno-2-methyl-propoxy)- 8 322 phenyl]-propyl}-/V,Λf-dιmethyl-
"NΥ'σ c ethane-1 ,2-dιamιne
Λ/-{1 -[4-(3-Dιmethylamιno-2-methyl-propoxy)- gg 336
"N'Y Ό phenyl]-butyl}-A/,W-dιmethyl- ethane-1 ,2-dιamιne
Λ/,/V-Dιmethyl-/V-[6-(3-pιpeπdιn-1 -yl-propoxy)- 89 272
1 ,2,3,4-tetrahydro-naphthalen-1 -yl]-ethane- M-87 1 ,2-dιamιne
Λ/,Λ/-Dιmethyl-/V-[6-(2-pιperιdιn-1 -yl-ethoxy)- 90 258
1 ,2,3,4-tetrahydro-naphthalen-1 -yl]-ethane- M-87 1 ,2-dιamιne
348
Λ/,Λ/-Dιmethyl-/V-{1 -[4-(2-pιperιdιn-1 -yl-ethoxy)- 92 334 phenyl]-butyl}-ethane-1 ,2-dιamιne
Λ/-{1 -[4-(3-Dιmethylamιno-propoxy)-phenyl]-butyl}- 93 322 ΛΛtø-dimethyl-ethane-l ,2-dιamιne
-N *^^0
Λ/,Λ/-Dιmethyl-/V-{1 -[4-(2-pιpeπdιn-1 -yl-ethoxy)- 95 348 phenyl]-butyl}-ethane-1 ,2-dιamιne
Examples 135, 14, 126 6
To a 10 mL round-bottom flask was added (102) (280 mg, 0.96 mmol) and dry MeOH (5 mL). Then, NaBH*. (74 mg, 1.93 mmol) was added at room temperature. After 1 hour, the reaction was then quenched with water, extracted into DCM and dried over Na2SO4. The material was purified by Biotage utilizing 4:1 EtOAc:MeOH to provide 270 mg (98%) of a white solid. Mass spec hit M+l, 292; LCMS >98% @ 230 nm and ELSD. Examples 14 and 126 are made by a substantially analogous procedure. Observed mass: Example 14 = 321, Example 126 = 375.
Example 142
Example 142 To a round-bottom flask, equipped with stir bar and septum, was placed (103) (300 mg, 1.03 mmol), KI (230 mg, 1.54 mmol) and NaH (78 mg, 95%dry, 3.09 mmol). Then, dry DMF (20 mL, 0.5 M) was added via syringe followed by chloroethylpiperidine (285 mg, 1.54 mmol). The reaction was allowed to stir at 50 degrees overnight. In the morning, the reaction was quenched with water, extracted into EtOAc (3 x 20 mL) and dried over brine. Column chromatography in 9:1 DCM:MeOH afforded 631934 an yellow oil (300 mg, 79%). Mass sec hit M+l, 404; LCMS >95% @ 230 nm and ELSD.
Example 246
(104) 3-Piperidinylpropanol(3.56g, 25 mmoles) in 4 ml DMF was added to a slurry of sodium hydride in 10 ml DMF at 0 C, and the reaction was stirred at 0 C.for 0.5 hr. The 4- fluorobenzonitrile in 6 ml was added at 0 C. The reaction was stirred at 0 C for 1 hr. and at RT overnight. Water and ether were carefully added. Separated the ether layer and extracted with water five times. The ether extract was dried over sodium sulfate, filtered and evaporated to give 6.0g(0.0246 mmoles, 98.4% yield). LCMS 1.61 min @254.0 nm 95.2%; @230.0 nm 89.5%; ELSD 1.71 min 100%; MS 1.59 min M + 1 = 245 good for product (104). Example 246 (104)
The nitrile(6.0g, 0.0246 mmoles) in 250 ml 2B EtOH with 2.5 g RaNi was hydrogenated at 80 C. for 8 hrs. Filtration and evaporation yielded 5.4 g oil(88.4 yield).
amine
Example 217 The 1-hydroxybenzotriazole hydrate(13.5 mg, 0.1 mmole), 1-piperidinepropionic acid(18.1 mg, 0.115 mmole), amine(248 mg, 0.1 mmole), polystyrene-carbodiimide(125 mg, 0.15 mmoles) and 2.5 ml chloroform, acetonitrile, t-butanol(5:l:l) in a 4 ml vial were rotated for four days. Polystyrene-trisamine(93J mg, 0.4 mmoles) was added and the reaction was rotated overnight. Filtered reaction through filter cartridge and evaporated to give 37.5 mg, 0.0967 mmole, 96.7% yield. LCMS ELSD 1.42 min 100%, MS 1.21 min M + 1 = 388 good for product.
Example Observed Mass
116 348
117 376
118 350
119 384
120 391
121 322
122 398
123 393
124 388
125 477
Example 15 The solution of diisopropylazodicarboxylate(3.93 ml, 20 mmoles) in 20 ml anhydrous THF was added dropwise with stirring to the cold solution of 4- hydroxyacetophenone(2.18 g, 16 mmoles), 3-diethylaminopropanol(2.23 ml, 15 mmoles) and triphenylphosphine(4.98 g, 19 mmoles) in 50 ml anhydrous THF over 45 minutes. The reaction was stirred in an ice bath for one hour and at room temperature for 18 hours. The solvent was evaporated and ether was added. This solution was extracted with dilute HC1(1.0 N) four times. These combined acidic extracts were extracted with ether, basified with a NaOH solution and extracted with ether three times. These combined ethereal extracts were dried over sodium sulfate, filtered and evaporated to give 3.41 g oil. LCMS 1.53 min @254.0 nm 97.4%; ELSD 1.59 min 91.1%; MS 1.58 min M+l=250 good for product (105).
In a 7 ml vial with cap, 4-(3-diethylaminopropyloxy)acetophenone(0.47 g, 0.19 mmoles), N-(2-aminoethyl)morpholine(0.039 ml, 0.3 mmoles) and macroporus cyanoborohydride(169 mg, 0.4 mmoles) in 2 ml dichloromethane with 0.2 ml glacial acetic were heated on shaker at 55° for 18 hours. Purified with a 3 ml extrelut cartridge hydrated with 3 ml water. The reaction solution was added and the cartridge was rinsed with dichloromethane(5 ml). The product was eluted with 10% triethylamine/dichloromethane. LCMS 1.14 min @254.0 nm 95.6%; @230.0 nm 95.3%; 1.20 min ELSD 95.3%; MS 1.14 min M+l=364 good for product. Example Observed Mass 15 364
16 348
17 308
18 362
19 336
20 377
21 391
1 336
22 381
231 363
24 362
25 359
26 336
27 376
Example 62
The solution of diisopropylazodicarboxylate (3.93 ml, 20 mmoles) in 20 ml anhydrous THF was added dropwise with stirring to the cold solution of 4- hydroxybenzaldehyde(1.95 g, 16 mmoles), 3-diethylaminopropanol(2.23 ml, 15 mmoles) and triphenylphosphine(4.98 g, 19 mmoles) in 50 ml anhydrous THF over 45 minutes. The reaction was stirred in an ice bath for one hour and at room temperature for 18 hours. The solvent was evaporated and ether was added. This solution was extracted with dilute HC1(1.0 N) four times. These combined acidic extracts were extracted with ether, basified with a NaOH solution and extracted with ether three times. These combined ethereal extracts were dried over sodium sulfate, filtered and evaporated to give 3.71 g oil. LCMS 1.47 min @254.0 nm 97.0%; ELSD 1.53 min 95.4%; MS 1.48 min M+l=236 good for product.
In a 7 ml vial with cap, 4-(3-diethylaminopropyloxy)benzaldehyde(0.59 g, 0.25 mmoles), N-(2-aminoethyl)morpholine(0.049 ml, 0.375 mmoles) and macroporus cyanoborohydride(210 mg, 0.5 mmoles) in 3 ml dichloromethane with 0.3 ml glacial acetic were heated on shaker at 40° briefly. Purified with 3 ml extrelut cartridge hydrated with 3 ml water. The reaction solution was added and the cartridge was rinsed with dicloromethane(5 ml). The product was eluted with 10% triethylamine/dichloromethane. LCMS 1.14 min ELSD 95.3%; MS 1.09 min M+l=350 good for product Example 62.
Example Observed Mass
629 350
63 334
47 294
48 348
49 348
50 322
51 363
52 377
61 322
53 349
54 348
70 345
71 322
72 362
73 364
59 376
74 348
104 320
113 420
114 410
107 334
103 334
Example 45
, water 4-Hydroxybenzaldehyde(2.44g, 20 mmoles), N-(3-Chloropropyl)piperidine hydrochloride, cesium carbonate(19J g, 60 mmoles) and potassium iodide in 14 ml dioxane with 0.7 ml water were stirred at 85° for 8 hours and at room temperature for 16 hours. Evaporated the decanted supernatant, added water to both (evaporated supernatant and solid) and extracted three times with ether. These combined ethereal extracts were washed three times with water, dried over sodium sulfate, filtered and evaporated to give
7.8 g oil. LCMS 1.48 min @254.0 nm 99.4%; @230.0 nm 89.6%; 1.51 min ELSD
99.4%; MS 1.49 min M+l=248 good for product. 300 mHz NMR(CDC13) good for structure (107).
In a 7 ml vial with cap, 4-[(3-N-piperidinyl)propyloxy]benzaldehyde(0.062 g, 0.25 mmoles), N-(2-aminoethyl)morpholine(0.049 ml, 0.375 mmoles) and macroporus cyanoborohydride(210 mg, 0.5 mmoles) in 3 ml dichloromethane with 0.3 ml glacial acetic were heated on shaker at 40 . The reaction was shaken at room temperature for 16 hours and at 40° for one hour. Purified with 3 ml extrelut cartridge hydrated with 3 ml water. The reaction solution was added and the cartridge was rinsed with dicloromethane(5 ml). The product was eluted with 10% triethylamine/dichloromethane. LCMS 1.13 min @230.0 nm 97.3%; 1.19 min ELSD 98.5%; MS 1.13 min M+l=362 good for product Example 45. Example Observed Mass
45 362
46 346
64 306
65 360
66 360
67 334
68 361
69 360
55 357
56 334
57 374
58 376
75 388
60 360
102 346
105 332
112 432
115 410
106 346
108 375
109 389
110 334
Example 100
Dimethyl-(3-{4-[l-(2-piperidin-l-yl-ethylamino)-ethyl]-phenoxy}-propyl)-amine To a 20 mL vial was placed (108) (42 mg, 0.19 mmol), amine (37 mg, 0.29 mmol), MP- CNBH3 (190 mg, 0.45 mmol, 2.37 mmol/g) and a 9:1 CHCl3:HOAc solution. The reaction was heated to 50 degrees overnight on a J-KEM heater/shaker block. The reaction was filtered, washed with DCM/MeOH. The material was then subjected to preparative HPLC purification to afford 5.8 mg (9%) example 100. As a clear oil. Mass spec hit M+l, 334; LCMS >89% @ 214 nm. In a procedure substantially similar to that for synthesis if Example 100, the following examples are made:
Example
Ammo Ketone Amine Product Name 13 MS
Dιmethyl-[3-(4-{1 -[3-(2-methyl- κ ι?ι 362
N^l pιperιdιn-1 -yl)-propylamιno]-
NHo 12
%N" — "O ethyl}-phenoxy)-propyl]-amιne
N Λ/-{1 -[4-(3-Dιmethylamιno-propoxy)- 613021 384
^T' "1 phenyl]-ethyl}-/V-ethyl-Λ/-m-tolyl-
-N'^^Ό NH ethane-1 ,2-dιamιne ^
I
O
(1 -{1 -[4-(3-Dιmethylamιno-propoxy)- 613011 320
\N phenyl]-ethyl}-pyrrolιdιn-3-yl)-
-N^-^^O HN dimethyl-amine
NH2 Dιmethyl-(3-{4-[1 -(1 -phenyl-ethyl in 327
*N'~^~V amιno)-ethyl]-phenoxy}- propyl)-amιne 96
Dιmethyl-(3-{4-[1 -(2-morpholιn-4-yl- 623901 335 ethylamιno)-ethyl]-phenoxy}-
^N^-^O O^P NH2 propyl)-amιne
Et
Λ/*-{1-[4-(3-Dιmethylamιno-propoxy) 97 363
Et' phenyl]-ethyl}-W1 , Λ/1 -diethyl-
-N^^O -NH, pentane-1 ,4-dιamιne 98
O
"> N [3-(4-{1 -[(1 -Ethyl-pyrro dιn-2-yl 623903 333
-U'^^O H2N' \ ) methyl)-amιno]-ethyl}-phenoxy)- propyl]-dιmethyl-amιne
H2N' ,0 Dιmethyl-(3-{4-[1 -(2-pιperιdιn-1 -yl- 100 333 ethylamιno)-ethyl]-phenoxy}- propyl)-amιne
O -(3-Azepan-1 -yl-propyl 101 361
-N---~-^o amιno)-ethyl]-phenoxy}-
HoN -o (3-{4-[1 propyi)-dιmethyl-amιne
HoN {1 -[4-(3-Pιperιdιn-1 -yl-propoxy)- 36 354 phenyl]-ethyl}-pyrιdιn- 2-ylmethyl-amιne
{1 -[4-(3-Pιperιdιn-1 -yl-propoxy)- 37 354 phenyl]-ethyl}-pyrιdιn- 4-ylmethyl-amιne
{1 -[4-(3-Pιperιdιn-1 -yl-propoxy)- 40 347 PG6-A40-154-21 phenyl]-ethyl}-(tetrahydro- furan-2-ylmethyl)-amιne
N-{ l-[4-(3-Diethylamino-propoxy)-phenyl]-ethyl}-N-(2-dimethylamino-ethyl)-C-phenyl- methanesulfonamide. To a 4 ml vial was placed Ν-{ l-[4-(3-Diethylamino-propoxy)- phenyl]-ethyl}-N',N'-dimethyl-ethane-l,2-diamine (22 mg, 0.07 mmol), phenyl- methanesulfonyl chloride (27 mg, 0.14 mmol), PS-DMAP (93 mg, 1.48 mmol/g), and CH2C12 (1.5 ml). The vial was agitated by means of a lab quake shaker for 4 h. To the solution was added PS-Trisamine (100 mg, 3.3 mmol, 3.0 mmol/g) and the reaction was allowed to agitate overnight to scavenge excess methansulfonyl chloride. Filtration, washing with CH2C12 and concentrating afforded N-{ l-[4-(3-Diethylamino-propoxy)- phenyl]-ethyl}-N-(2-dimethylamino-ethyl)-C-phenyl-methanesulfonamide. Mass spec hit M+l, 476: LCMS >93% @ 230 nm and ELSD.
Sulfonyl Chloride Product Name Example MS (M+1)
^~ _ Λ/-{1-[4-(3-Diethylamino-propoxy)-phenyl]-ethyl}- 30 462
\==/ 2 Λ/-(2-dimethylamino-ethyl)-benzenesulfonamide
S Thiophene-2-sulfonic acid {1-[4-(3- 33 468
[T -Sθ2CI diethylamino-propoxy)-phenyl]- ethylj-(2-dimethylamino-ethyl)-amide
F3C 2,2,2-Trifluoro-ethanesulfonic acid {1-[4-(3- 31 468
^S0 CI diethylamino-propoxy)-phenyl]-ethyl}-
(2-dimethylamino-ethyl)-amide
Utilizing the procedures provided herein, in addition to methods known in the art, compounds of Formula I and Formula II were prepared. Structural figures for representative examples of Formula I and Formula II are shown the following pages.
ill
The compound of Formula I is preferably formulated in a unit dosage form prior to administration. Therefore, yet another embodiment of the present invention is a pharmaceutical composition comprising a compound of Formula I and one or more pharmaceutically acceptable carriers, diluents or excipients.
The present pharmaceutical compositions are prepared by known procedures using well-known and readily available ingredients. In making the formulations of the present invention, the active ingredient (Formula I compound) will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semisolid or liquid material that acts as a vehicle, excipient, or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosol (as a solid or in a liquid medium), soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient. The compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e., antihistaminic activity and the like. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices. Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injections or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration, Such liquid forms include solutions, suspensions and emulsions.
The compounds of the invention may also be deliverable transdermally. The transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as a re conventional in the art for this purpose. Preferably the compound is administered orally.
Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose. The quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 0.01 milligrams to about 1,000 milligrams, preferably from about 0.01 to about 950 milligrams, more preferably from about 0.01 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application. The actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art. Generally, the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day. Utility
Compounds of Formula I are effective as histamine H3 receptor antagonists. More particularly, these compounds are selective histamine H3 receptor antagonists that have little or no affinity for histamine receptor GPRv53(H4R). As selective antagonists, the compounds of Formula I are useful in the treatment of diseases, disorders, or conditions responsive to the inactivation of the histamine H3 receptor, including but not limited to obesity and other eating-related disorders. It is postulated that selective antagonists of H3R will raise brain histamine levels and possibly that of other monoamines resulting in inhibition of food consumption while minimizing peripheral consequences. Although a number of H3R antagonists are known in the art, none have proven to be satisfactory obesity drugs. There is increasing evidence that histamine plays an important role in energy homeostasis. Histamine, acting as a neurotransmitter in the hypothalamus, suppressed appetite. Histamine is an almost ubiquitous amine found in many cell types and it binds to a family of G protein-coupled receptors (GPCRs). This family provides a mechanism by which histamine can elicit distinct cellular responses based on receptor distribution. Both the H1R and H2R are widely distributed. H3R is primarily expressed in the brain, notably in the thalamus and caudate nucleus. High density of expression of H3R was found in feeding center of the brain. A novel histamine receptor GPRv53 has been recently identified. GPRv53 is found in high levels in peripheral white blood cells; only low levels have been identified in the brain by some investigators while others cannot detect it in the brain. However, any drug discovery effort initiated around H3R must consider GPRv53 as well as the other subtypes. The inventive compounds can readily be evaluated by using a competitive inhibition Scintillation Proximity Assay (SPA) based on a H3R binding assay using [3H] methylhistamine as ligand. Stable cell lines, including but not limited to HEK can be transfected with cDNA coding for H3R to prepare membranes used for the binding assay. The technique is illustrated below (Example 3) for the histamine receptor subtypes. Membranes isolated as described in Example 3 were used in a [35S]GTPχS functional assay. Binding of [35S]GTPχS to membranes indicates agonist activity. Compounds of the invention of Formula I were tested for their ability to inhibit binding in the presence of agonists. Alternately, the same transfected cell lines were used for a cAMP assay wherein H3R agonists inhibited forskolin-activated synthesis of cAMP. Compounds of Formula I were tested for their ability to permit forskolin -stimulated cAMP synthesis in the presence of agonist. Preparation of Histamine Receptor Subtype Membranes A. Preparation H1R membranes cDNA for the human histamine 1 receptor (H1R) was cloned into a mammalian expression vector containing the CMV promoter (pcDNA3.1(+), Invitogen) and transfected into HEK293 cells using the FuGENE Tranfection Reagent (Roche Diagnostics Corporation). Transfected cells were selected using G418 (500 μ/ml). Colonies that survived selection were grown and tested for histamine binding to cells grown in 96-well dishes using a scintillation proximity assay (SPA) based radioligand binding assay. Briefly, cells, representing individual selected clones, were grown as confluent monolayers in 96-well dishes (Costar Clear Bottom Plates, #3632) by seeding wells with 25,000 cells and growing for 48 hours (37°C, 5% CO2). Growth media was removed and wells were rinsed two times with PBS (minus Ca2+ or Mg2+). For total binding, cells were assayed in a SPA reaction containing 50mM Tris-HCL (assay buffer), pH 7.6, lmg wheat germ agglutinin SPA beads (Amersham Pharmacia Biotech, #RPNQ0001), and 0.8nM 3H-pyril amine (Net-594, NEN) (total volume per well = 200μl). Astemizole (lOμM, Sigma #A6424) was added to appropriate wells to determine nonspecific binding. Plates were covered with FasCal and incubated at room temperature for 120 minutes. Following incubation, plates were centrifuged at l,000rpm (~800g) for 10 minutes at room temperature. Plates were counted in a Wallac Trilux 1450 Microbeta scintillation counter. Several clones were selected as positive for binding, and a single clone (H1R40) was used to prepare membranes for binding studies. Cell pellets, representing -10 grams, were resuspended in 30ml assay buffer, mixed by vortexing, and centrifuged (40,000g at 4°C) for 10 minutes. The pellet resuspension, vortexing, and centrifugation was repeated 2 more times. The final cell pellet was reusupened in 30ml and homogenized with a Polytron Tissue Homogenizer. Protein determinations were done using the Coomassie Plus Protein Assay Reagent (Pierce). Five micrograms of protein was used per well in the SPA receptor-binding assay. B. Preparation H2R membranes cDNA for the human histamine 2 receptor was cloned, expressed and transfected into HEK 293 cells as described above. Histamine binding to cells was assayed by SPA described above. For total binding, cells were assayed in a SPA reaction containing 50mM Tris-HCl (assay buffer), pH 7.6, lmg wheat germ agglutinin SPA beads
(Amersham Pharmacia Biotech, #RPNQ0001), and 6.2nM 3H-tiotidine (Net-688, NEN) (total volume per well = 200μl). Cimetidine (lOμM, Sigma #C4522) was added to appropriate wells to determine non-specific binding.
Several clones were selected as positive for binding, and a single clone (H2R10) was used to prepare membranes for binding studies. Five micrograms of protein was used per well in the SPA receptor-binding assay.
C. Preparation of H3R membranes cDNA for the human histamine 3 receptor was cloned and expressed as described in Example 1, above. Transfected cells were selected using G418 (500 μ/ml), grown, and tested for histamine binding by the SPA described above. For total binding, cells were assayed in a SPA reaction described above containing 50mM Tris-HCL (assay buffer), pH 7.6, lmg wheat germ agglutinin SPA beads (Amersham Pharmacia Biotech, #RPNQ0001), and InM ( 3H)-n-alpha-methylhistamine (NEN, NET1027) (total volume per well = 200μl). Thioperimide was added to determine non-specific binding. Several clones were selected as positive for binding, and a single clone (H3R8) was used to prepare membranes for binding studies described above. Five micrograms of protein was used per well in the SPA receptor-binding assay.
All compounds set forth in examples 1 to 322 exhibited affinity for the H3 receptor greater than 1 uM. Preferred compounds of the invention exhibited affinity for the H3 receptor greater than 200 nM. Most preferred compounds of the invention exhibit affinity for the H3 receptor greater than 20 nM.
D. Preparation of GPRv53 Membranes cDNA for the human GPRv53 receptor was cloned and expressed as described in
Example 1, above. Transfected cells were selected, tested for histamine binding, and selected. HEK293 GPRv53 50 cells were grown to confluency in DMEM F12 (Gibco) supplemented with 5 % FBS and 500 ug/ml G418 and washed with Delbecco's PBS (Gibco) and harvested by scraping. Whole cells were homogenized with a Polytron tissuemizer in binding buffer, 50 mM Tris pH 7.5. Cell lysates, 50 ug, were incubated in 96 well dishes with 3 nM (3H) Histamine and compounds in binding buffer for 2 hours at room temperature. Lysates were filtered through glass fiber filters (Perkin Elmer) with a Tomtec cell harverster. Filters were counted with melt-on scintillator sheets (Perkin Elmer) in a Wallac Trilux 1450 Microbeta Scintillation counter for 5 minutes.
Pharmacological Results cAMP ELISA
HEK293 H3R8 cells prepared as described above were seeded at a density of 50,000 cells/well and grown overnight in DMEM/F12 (Gibco) supplemented with 5 % FBS and 500 ug/ml G418. The next day tissue culture medium was removed and replaced with 50 μl cell culture medium containing 4 mM 3-isobutyl-l-methylxanthine (Sigma) and incubated for 20 minutes at room temperature. Antagonist were added in 50 μl cell culture medium and incubated for 20 minutes at room temperature. Agonist R (-)α methylhistamine (RBI) at a dose response from lxlO"10 to lxlO"5 M was then added to the wells in 50 μl cell culture medium and incubated for 5 minutes at room temperature. Then 50 μl of cell culture medium containing 20 μM Forskolin (Sigma) was added to each well and incubated for 20 minutes at room temperature. Tissue culture medium was removed and cells were lysed in 0.1M HCl and cAMP was measured by ELISA (Assay Designs, Inc.).
[35S] GTP γ [S] Binding Assay Antagonist activity of selected compounds was tested for inhibition of [35S] GTP γ [S] binding to H3R membranes in the presence of agonists. Assays were run at room temperature in 20 mM HEPES, 100 mM NaCl ,5 mM MgCl2 and 10 uM GDP at pH 7.4 in a final volume of 200 ul in 96-well Costar plates. Membranes isolated from H3R8- expressing HEK293 cell line (20 ug/well) and GDP were added to each well in a volume of 50 μl assay buffer. Antagonist was then added to the wells in a volume of 50 μl assay buffer and incubated for 15 minutes at room temperature. Agonist R(-)alpha methylhistamine (RBI) at either a dose response from lxlO"10 to lxlO"5 M or fixed concentration of 100 nM were then added to the wells in a volume of 50 μl assay buffer and incubated for 5 minutes at room temperature. GTP γ [35S] was added to each well in a volume of 50 μl assay buffer at a final concentration of 200 pM, followed by the addition of 50 μl of 20 mg/ml WGA coated SPA beads (Amersham). Plates were counted in Wallac Trilux 1450 Microbeta scintillation counter for 1 minute. Compounds that inhibited more than 50% of the specific binding of radioactive ligand to the receptor were serially diluted to determine a K[i ](nM). The results are given below the indicated compound.
Table 1
Compound Ki (nM) Structure
Example 2 1.48, 0.95
Example 1 1 .4
To investigate the selectivity of the antagonists for the histamine receptors, a competitive binding assay described above was performed. The ability of example 13 land 250 (structures given above) to selectively inhibit binding to H3R, H1R, H2 and H4R was determined. Importantly, the identification of H3R-specific antagonists that do bind the newly identified H4R was demonstrated. Until the present invention, most known H3R antagonists also bound H4R. As demonstrated in Table 2, example 131 and example 250 did not inhibit binding H4R compare to H3R. To our knowledge, the study in Table 2 is the first demonstration of a H3R specific antagonist. Table 2 Ki (nM)
Non-imidazole containing histamine H3 receptor antagonists disclosed in the literature generally have very poor pharmacokinetic properties (see J. Apelt, et al, J. Med. Chem. 2002, 45, 1128-1141). Compounds of this invention have markedly and unexpectedly improved pharmacokinetic properties. Male Sprague Dawley Rats (n=3 per dose arm) were separately dosed with 3 mg/kg iv or 10 mg/kg po of compound examples 131 and 271 (vehicle: 5% ethanol/water or water respectively; dose volume: 1 rnL/kg iv, 10 mlJkg po). Approximately 0.5 mL of blood was collected in heparin collection tubes at multiple time points over an 8 or 24-hour period for examples 131 and 271 respectively, and the samples were analyzed using LC/MS/MS. In this manner compound example 131 was found to have an oral bioavailability of 58% (AUC 0-24hr; po/iv ratio) and an oral half-life of 10.4 + 4.2 hours (+SEM). Compound example 271 was found to have an oral bioavailability of 69% (AUC 0-24hr; po/iv ratio) and an oral half-life of 71.9 ± 3.3 hours (±SEM).
From the above description, one skilled in the art can ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.

Claims

WHAT IS CLAIMED IS:
1. A compound structurally represented by Formula I
or pharmaceutically acceptable salts thereof wherein:
X is O, NR7 or S;
Rl is hydrogen,
C -Cg alkyl optionally substituted with 1 to 4 halogens,
(CHR5)n-C3-C7 cycloalkyl,
(CHR5)n aryl,
(CHR5)n heteroaryl, or
(CHR5)n-O(CHR5)n-aryl;
R2 is independently R****, or
COR! ' or cyclized with the attached nitrogen atom at the Rl position to form a 4, 5, or 6 member carbon ring, wherein one of said carbons is optionally replaced by one of
O, S, NR-** or CO, or wherein the ring formed by R1 and R2 is optionally substituted one to two times with C1-C4 alkyl;
R3 is independently C3-C cycloalkylene, or C - C4 alkylene optionally substituted; R4 is hydrogen, halogen, C1 -C4 alkyl, (CHR5)n-C3-C7 cycloalkyl,
(CHR5)n aryl, (CHR5)n heteroaryl, (CHR5)n-O(CHR5)n-aryl or CO or cyclized with R5 to from a cyclopropyl ring;
R5 is hydrogen , or C1 -C4 alkyl;
R is hydrogen, halo or cyclized with the attached carbon atom at the R position to form a 5 to 6 member carbon ring, cyclized with the attached carbon atom at the R^ position to form a 5 to 6 member heterocyclic ring or
R is hydrogen,
Ci-Cg alkyl optionally substituted with 1 to 4 halogens,
(CHR5)n-C3-C7 cycloalkyl, (CHR5)n aryl,
(CHR5)n heteroaryl,
(CHR5)n-O(CHR5)n-aryl,
SO2R1 or Cyclized with attached carbon on R8 to from a 5, 6, or 7 membered carbon ring optionally substituted with R9> CF3, or CN, optionally one of the said carbons is replaced by R NR^ CO;
R* is hydrogen, a bond, Ci-Cg alkyl
-SO2 R9, -CO2 R10, -CO R9,
-CONH R10;
R9 is hydrogen, halogen, Ci -Cg alkyl optionally substituted with 1 to 4 halogens,
C3-C7 cycloalkyl, aryl,
CH2 aryl, heteroaryl, heterocycle,
-O(CHR5)n-aryl,
-COR1, -CONR1 R2, -SO2R1, -OR1,
-N(R1)2, -NR1 R2, -CH2NR1 R2, -CONR1 R2 -NHSO2R1, -NO2,
-CO2R1, -SO2N(R1)2,
-S(O)nRi, -OCF3ι -CH2SR5, R ^ is hydrogen, halogen,
Cj-Cg alkyl optionally substituted with 1 to 4 halogens, C3-C7 cycloalkyl, aryl,
CH2 aryl, heteroaryl, heterocycle,
-COR1, -CONR1 R2, -SO2R1, -N(Rl)2,
-NR1 R2, -CH2NR1 R2,
-CONR1 R2 -CO2R1, -SO2N(R1)2,
-CH2SR5, and n is 0 - 4.
2. A compound of claim 1, structurally represented by Formula II
or pharmaceutically acceptable salts thereof where:
X is O, N or S;
R1' is hydrogen,
C^-Cg alkyl (optionally substituted with 1 to 4 halogens or C1-C4 alkyls),
(CHR5')n-C3-C7 cycloalkyl,
(CHR5')n aryl,
(CHR5')n heteroaryl, or
(CHR5 ' )n-O(CHR5 ' )n-aryl ;
R2' is independently R1 , or cyclized with the attached nitrogen atom at the R1 position to form a 5 to 6 member carbon ring (optionally one of said carbons is replaced by one of O, S or N);
R3' is independently Cj- C4 alkyl; R4' is hydrogen, halogen, C1 -C4 alkyl,
(CHR5')n-C3-C7 cycloalkyl, (CHR5')n aryl,
(CHR5')n heteroaryl,
(CHR5')n-O(CHR5)n-aryl or carbonyl;
R**>' is hydrogen or C1-C4 alkyl;
R6' is hydrogen, or cyclized with the attached carbon atom at the R-5 position to form a 5 to 6 member carbon ring, or cyclized with the attached carbon atom at the R^ position to form a 5 to 6 member heterocyclic ring;
R7' is hydrogen,
Ci -Cg alkyl (optionally substituted with 1 to 4 halogens or C1-C4 alkyls), (CHR5')n-C3-C7 cycloalkyl,
(CHR5')n aryl,
(CHR5')n heteroaryl,
(CHR5 ' )n-O(CHR5 ' )n-aryl
R8' is hydrogen, halogen,
Cj-Cg alkyl (optionally substituted with 1 to 4 halogens or C1-C4 alkyls), C3-C7 cycloalkyl, aryl, heteroaryl,
-O(CHR5')n-aryl,
-COR1, -SO Rr,
-OR1,
-CN, -CF3,
-N(Rl')2, -NHSO2Rr,
-NO2,
-CO2Rr,
-SO2N(R1')2,
-OCF3; and n is 0 - 4.
3. The compound of Claim 1, wherein X is nitrogen.
4. The compound of claim 1 or 3 wherein the compound is a para disubstituted benzene.
5. The compound of any of claims 1, or 3-4 wherein R6 is cyclized with the attached carbon atom at R7 to form, including the fused benzene ring, a substituted tetrahydroisoquinoline ring.
6. The compound of any of claims 1, or 3-4 wherein X is nitrogen, and wherein R7 and R8 are cyclized to form, together with X, a pyrrolidine ring, and wherein R is
-CH2-N-pyrrolidinyl .
7. The compound of any of claims 1, or 3-6, selected from the group consisting of: Example
Structure Number
Chiral
I CH,
CH CH
or a pharmaceutically acceptable salt or solvate thereof.
8. A compound of claim 1 wherein the compound has the structure: or a pharmaceutically acceptable salt or solvate thereof.
9. A compound of claim 1 wherein the compound has the structure:
or a pharmaceutically acceptable salt or solvate thereof.
10. A compound of claim 1 wherein the compound has the structure:
or a pharmaceutically acceptable salt or solvate thereof.
11. A compound of claim 1 wherein the compound has the structure:
or a pharmaceutically acceptable salt or solvate thereof.
12. A compound of claim 1 wherein the compound has the structure:
or a pharmaceutically acceptable salt or solvate thereof.
13. A compound of claim 1 wherein the compound has the structure:
or a pharmaceutically acceptable salt or solvate thereof.
14. A pharmaceutical composition which comprises a compound of any of claims 1- 14 and a pharmaceutically acceptable carrier.
15. A method of selectively increasing histamine levels in cells by contacting the cells with an antagonist of the histamine H3 receptor, said antagonists being a compound of any of claims 1-14.
16. A method of selectively increasing histamine levels in cells by contacting the cells with an antagonist of the histamine H3 receptor, said antagonists being a compound of Claim 2.
17. A method of selectively increasing histamine levels in cells by contacting the cells with an antagonist of the histamine H3 receptor, said antagonists being a compound of Claim 7.
18. A method of selectively increasing histamine levels in cells by contacting the cells with an antagonist of the histamine H3 receptor, said antagonists being a compound of Claim 9.
19. A method of selectively increasing histamine levels in cells by contacting the cells with an antagonist of the histamine H3 receptor, said antagonists being a compound of Claim 11.
20. The method of Claim 15 wherein the antagonist is characterized by having little or no binding affinity for the histamine receptor H4R.
21. A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of any of Claims 1-14.
22. A method for treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of any of claims 1-14.
23. A method for treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Claim 2.
24. A method for treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Claim 7.
25. A method for treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Claim 9.
26. A method for treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Claim 11.
EP02723329A 2001-03-23 2002-03-21 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses Withdrawn EP1379493A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27823001P 2001-03-23 2001-03-23
US278230P 2001-03-23
PCT/US2002/006644 WO2002076925A2 (en) 2001-03-23 2002-03-21 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
EP1379493A2 true EP1379493A2 (en) 2004-01-14

Family

ID=23064195

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02723329A Withdrawn EP1379493A2 (en) 2001-03-23 2002-03-21 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses

Country Status (5)

Country Link
EP (1) EP1379493A2 (en)
JP (1) JP2004532834A (en)
AU (1) AU2002254114A1 (en)
CA (1) CA2441080A1 (en)
WO (1) WO2002076925A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002604A1 (en) 2001-12-10 2004-01-01 Richard Apodaca Phenylalkynes
ES2259728T3 (en) 2001-12-10 2006-10-16 Ortho-Mcneil Pharmaceutical, Inc. PHENYLALKINS.
DE10235312A1 (en) 2002-08-01 2004-02-12 Basf Ag Process for the preparation of aminoalkoxybenzylamines and aminoalkoxybenzonitriles as intermediates
GB0224083D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
WO2004037800A1 (en) * 2002-10-22 2004-05-06 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
EP1556046A1 (en) 2002-10-23 2005-07-27 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
EP1558595B1 (en) 2002-10-23 2009-11-25 Janssen Pharmaceutica N.V. Piperazinyl and diazapanyl benzamides and benzthioamides
CA2523431A1 (en) 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
DE10325258B4 (en) 2003-06-03 2008-08-21 Diehl Aerospace Gmbh Aircraft cabin equipment control
ATE547404T1 (en) 2003-09-22 2012-03-15 Msd Kk PIPERIDINE DERIVATIVES
EP1720861A2 (en) 2004-02-25 2006-11-15 Eli Lilly And Company Histamine h3 receptor antagonists, preparation and therapeutic uses
BRPI0509298A (en) * 2004-04-01 2007-09-18 Lilly Co Eli compound, pharmaceutical composition, methods of inhibiting histamine h3 receptor in a mammal, to treat or prevent a nervous system disorder, obesity, and a disorder or disease, and, use of a compound
JP2007532638A (en) * 2004-04-14 2007-11-15 アストラゼネカ・アクチエボラーグ Arylglycinamide derivatives and their use as NK1 antagonists and serotonin reuptake inhibitors
CN1980896A (en) 2004-05-07 2007-06-13 詹森药业有限公司 Scalable synthesis of imidazole derivatives
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1593679A1 (en) * 2004-05-07 2005-11-09 Warner-Lambert Company LLC 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands
ES2346665T3 (en) * 2004-05-07 2010-10-19 Warner-Lambert Company Llc DERIVATIVES OF PHENOL AND THIOPHENOL 3- OR 4-USEFUL MONOSUSTITUTES AS LIGANDOS OF H3.
US20050256309A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
FR2870846B1 (en) 2004-05-25 2006-08-04 Sanofi Synthelabo TETRAHYDROISOQUINOLYLSULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
DE602005004404T2 (en) 2004-06-02 2009-01-15 F. Hoffmann-La Roche Ag AS HISTAMIN-3 RECEPTOR LIGANDS INSERTABLE NAPHTHALENE DERIVATIVES
EP1756051B1 (en) 2004-06-02 2012-09-12 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
CA2575081C (en) 2004-07-26 2013-05-07 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
CN101006082B (en) 2004-08-23 2010-09-29 伊莱利利公司 Histamine H3 receptor agents, methods of preparation and therapeutic uses
JP5057982B2 (en) * 2004-10-18 2012-10-24 イーライ リリー アンド カンパニー Histamine H3 receptor inhibitor, manufacture and therapeutic use
MX2007004465A (en) * 2004-10-19 2007-05-07 Hoffmann La Roche Quinoline derivatives.
BRPI0608523A2 (en) * 2005-03-17 2010-11-16 Lilly Co Eli compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods for inhibiting h3 histamine receptor in a mammal, for treating or preventing a nervous system disorder, for treating or preventing obesity, and for treating or preventing a disorder or disease, and, use of a compound or a salt thereof
EP1707204A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands
AU2006232871B9 (en) * 2005-04-01 2011-11-24 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1717233A1 (en) 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
MX2007016216A (en) * 2005-07-01 2008-03-11 Lilly Co Eli Histamine h3 receptor agents, preparation and therapeutic uses.
SI1948607T1 (en) 2005-09-16 2010-07-30 Janssen Pharmaceutica Nv Cyclopropyl amines as modulators of the histamine h3 receptor
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
CA2624625A1 (en) * 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
EP1790646A1 (en) * 2005-11-24 2007-05-30 Sanofi-Aventis Isoquinoline und benzo[h]isoquinoline derivatives, their preparation and their therapeutical application as antagonists of histamine H3 receptor .
WO2007069053A1 (en) * 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007099423A1 (en) * 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
CA2679735A1 (en) 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
WO2009036144A1 (en) 2007-09-12 2009-03-19 Wyeth Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
WO2010026113A1 (en) * 2008-09-03 2010-03-11 Evotec Neurosciences Gmbh Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010052222A1 (en) * 2008-11-07 2010-05-14 Evotec Neurosciences Gmbh (dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
AR080375A1 (en) 2010-03-05 2012-04-04 Sanofi Aventis PROCEDURE FOR THE PREPARATION OF 2- (CYCLOHEXIMETHYL) -N- {2 - [(2S) -1-METHYLPIRROLIDIN-2-IL] ETIL} -1,2,3,4-TETRAHYDROISOCHINOLINE- 7-SULFONAMIDE
US9079888B2 (en) * 2011-02-23 2015-07-14 Suven Life Sciences Limited Compounds as histamine H3 receptor ligands
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
EP2745876A1 (en) * 2012-12-21 2014-06-25 Prous Institute for Biomedical Research, S.A. Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
ES2933350T3 (en) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (en) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Polymorphic form of diaryl macrocycle
CN106995410B (en) * 2016-01-26 2021-03-02 江苏恩华药业股份有限公司 Lactam derivative and application thereof
EP3409658B9 (en) * 2016-01-29 2024-07-17 ONO Pharmaceutical Co., Ltd. Tetrahydronaphthalene derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2810719A (en) * 1954-10-19 1957-10-22 Abbott Lab Morpholino alkyl ethers of hydroxybenzoic acid esters
HU187208B (en) * 1982-12-28 1985-11-28 Richter Gedeon Vegyeszet Process for production of new dialcil-amino-alcoxi-benzoalcohole derivates, their acid additional and quaterner soils and medical preparates consisting of them
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
PT1025077E (en) * 1997-10-15 2007-05-31 Wyeth Corp Novel aryloxy-alkyl-dialkylamines
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
ATE354568T1 (en) * 2000-08-08 2007-03-15 Ortho Mcneil Pharm Inc NON-IMIDAZOLE ARYLOXYPIPERIDINE AS H3 RECEPTOR LIGANDS
CA2448729A1 (en) * 2000-11-20 2002-05-23 Biovitrum Ab Piperazinyl and piperidyl substituted heterocyclic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02076925A2 *

Also Published As

Publication number Publication date
WO2002076925A2 (en) 2002-10-03
JP2004532834A (en) 2004-10-28
CA2441080A1 (en) 2002-10-03
AU2002254114A1 (en) 2002-10-08
WO2002076925A3 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
EP1379493A2 (en) Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
US7902191B2 (en) Histamine H3 receptor antagonists, preparation and therapeutic uses
US4806547A (en) Isoquinoline derivatives, analgesic compounds thereof and method of treating pain
KR20020067589A (en) Phenylpiperazinyl derivatives
CN101014581A (en) Novel piperidine derivative for the treatment of depression
FI85266B (en) FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA 1,4-DISUBSTITUERADE PIPERAZINDERIVAT.
US7314937B2 (en) Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
JPH06503073A (en) indane derivative
EP1585731A2 (en) Histamine h3 receptor antagonists, preparaton and therapeutic uses
US20060089347A1 (en) Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses
RU2127732C1 (en) Bis-phenylpiperazine nicotinic acid esters, method of their synthesis (variants), pharmaceutical composition, method of treatment of patients with central nervous system disorders
JP2008509962A (en) 5-HT7 receptor antagonist
FI84604B (en) FRUIT PROTECTION OF ANTIPSYCOTIS 8- / 4- / 4- (1-OXO-1,2-BENZISOTIAZOL-3-YL) -1-PIPERAZINYL / BUTYL / -8-AZASPIRO / 4,5 / DECANE-7,9- DION ELLER SALT DAERAV.
EP1861360B1 (en) Pyrrolidine derivatives as histamine h3 receptor antagonists
CA2424979A1 (en) 2,2-diphenylbutanamide derivatives and medicines containing the same
WO1990007502A1 (en) Decahydroisoquinoline compounds
JP2008509961A (en) 5-HT7 receptor antagonist
CN101010301A (en) 5-HT7 receptor antagonists
CN1956952B (en) Histamine H3 receptor agents, preparation and therapeutic uses
US7056922B2 (en) Acylamino cyclopropane derivatives
MXPA06015267A (en) Diazabicyclic histamine-3 receptor antagonists.
AU691468B2 (en) Ring-closed dihydropyridines and their use in the preparation of pharmaceutical compositions
WO2019097282A1 (en) Isoindoline derivatives for the treatment of cns diseases
Paluchowska et al. Structure‐Activity Relationship Studies of CNS Agents, Part 31 [1]: Analogs of MP 3022 with a Different Number of Nitrogen Atoms in the Heteroaromatic Fragment—New 5‐HT1A Receptor Ligands
Sparatore et al. 2-{4-[3-(4-Aryl/heteroaryl-1-piperazinyl) propoxy] phenyl}-2H-benzotriazoles and their N-oxides as ligands for serotonin and dopamine receptors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20040318

17Q First examination report despatched

Effective date: 20060901

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070112